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Abstract
Background After the ﬁrst investigational study on the use of extracorporeal photopheresis for the treatment of cuta-
neous T-cell lymphoma was published in 1983 with its subsequent recognition by the FDA for its refractory forms, the
technology has shown signiﬁcant promise in the treatment of other severe and refractory conditions in a multi-disciplin-
ary setting. Among the major studied conditions are graft versus host disease after allogeneic bone marrow transplanta-
tion, systemic sclerosis, solid organ transplant rejection and inﬂammatory bowel disease.
Materials and methods In order to provide recognized expert practical guidelines for the use of this technology for all
indications the European Dermatology Forum (EDF) proceeded to address these questions in the hands of the recognized
© 2013 The Authors. Journal of the European Academy of Dermatology and Venereology
published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
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experts within and outside the ﬁeld of dermatology. This was done using the recognized and approved guidelines of EDF
for this task.
Results and conclusion These guidelines provide at present the most comprehensive available expert recommenda-
tions for the use of extracorporeal photopheresis based on the available published literature and expert consensus
opinion.
Accepted: 7 October 2013
Introduction
Extracorporeal photopheresis (ECP, also known as extracorporeal
photochemotherapy, extracorporeal photoimmunotherapy or just
photopheresis) is a leukapheresis-based therapy that is available
at more than 200 centres worldwide.1 During ECP, the patient’s
whole blood is processed outside the body: blood is collected via
an ante-cubital vein, or via a permanent catheter if access is cum-
bersome, and the white blood cells are separated from the red
blood cells and plasma by centrifugation in a device that is specif-
ically constructed for the procedure. The white cells are exposed
to ultraviolet A (UVA) light in a separate plastic chamber, and
then returned to the patient.2 Initially, when this methodology
was first developed, patients treated with ECP were given oral
8-methoxypsoralen (8-MOP) to produce an effective plasma
concentration, and their blood was then leukapheresed.1 This
meant that they were still exposed to the gastrointestinal (GI) and
ocular side-effects of psoralen, which include nausea and vomit-
ing; moreover, differences in GI absorption due to individual var-
iability3 resulted in inconsistent blood concentrations of 8-MOP.1
To avoid the problems associated with oral 8-MOP, the proce-
dure was subsequently modified to use a liquid formulation of
8-MOP (UVADEX; Therakos Inc. West Chester, Pennsylvania,
USA), which is added directly to the buffy-coat/plasma blood
fraction circulating through the plastic chamber before UVA radi-
ation and re-infusion. This eliminated the side-effects of 8-MOP,
as well as the need for pre-medication with this drug and moni-
toring of its blood levels.4
The first investigational study of ECP in cutaneous T-cell lym-
phoma (CTCL) was completed in 1983,5 and the first system for
ECP, which was a closed system (UVAR; Therakos), was
granted approval by the United States Food and Drug Adminis-
tration in 1988, followed by multiple approvals in Europe and
around the world. Although ECP was initially developed for use
in CTCL, it has shown promising efficacy in a number of other
severe and difficult-to-treat conditions, most widely in graft-ver-
sus-host disease (GVHD) after allogeneic stem cell transplanta-
tion, but also in systemic sclerosis, prevention and treatment of
rejection in solid organ transplantation, Crohn’s disease and var-
ious other diseases.1,6
Several closed and open ECP systems are now available for clin-
ical use, and some of the currently used approaches are compared
in Table 1.7 In a closed ECP system (i.e. a ‘one-step’ method), the
cell separation, drug photoactivation and re-infusion stages are
fully integrated and automated and all the components are
validated for use together, tested and approved for use with meth-
oxsalen (Table 2). There is no risk of improper reinfusion when
they are used according to their labelling and the risk of infection
and contamination associated with the medical device itself is
low. Open ECP systems use separate devices for cell separation
and drug photoactivation (‘two-step’ methods), which have not
been validated for use together: the combination of a device
approved for separation and one approved for photoactivation is
not equivalent to a device approved for ECP. Although the com-
ponents may be CE marked or have FDA approval, they are not
specifically approved for photopheresis (Table 2). As several steps
are involved in delivering therapy, there is a potential risk of
infection and contamination, as well as a risk of cross-contamina-
tion and patient re-infusion error. In general, open systems can
only be used by certified centres for handling blood components
separately, whereas the closed systems do not have this limitation.
Regardless of the system used, treatment with ECP is usually
well-tolerated and no severe World Health Organization grade
III–IV side-effects have been reported. A few patients may expe-
rience transient hypotension during treatment, and mild anae-
mia and/or thrombocytopenia have also been reported. Some
patients are not suitable for treatment with ECP, including those
with: a known sensitivity to psoralen compounds such as 8-
MOP; comorbidities that may result in photosensitivity; aphakia
(UVADEX Sterile Solution is contraindicated in patients with
aphakia because of the significantly increased risk of retinal
damage due to the absence of lenses), pregnancy; history of hep-
arin-induced thrombocytopenia, unsatisfactory cardio-circula-
tory function and low haematocrit values. In addition, special
care needs to be taken in patients with a low bodyweight, in chil-
dren and in those with problematic venous access. In these con-
texts, specific small port systems with an appropriate blood flow
per minute should be used.
Ideally, ECP treatment should be initiated as early as possible
after the indication is confirmed, which, in most cases, is as sec-
ond-line therapy after first-line therapy has failed. At the present
time, ECP treatments are generally performed as in-patient ther-
apy in most centres in Europe. Monitoring before and during
treatment should be based on the standards of care for each indi-
cation. Even though heparin is registered for use with ECP, the
use of either heparin or acid citrate dextrose as anticoagulants
during ECP can be decided on the basis of the operating prac-
© 2013 The Authors. Journal of the European Academy of Dermatology and Venereology
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tices in individual centres and adjusted according to individual
patients’ medical conditions (e.g. danger of increased bleeding,
etc.). While the use of UVA protective glassware is recom-
mended (based on experience with PUVA and oral 8-MOP), it
does not appear to be necessary due to the very low levels of
psoralen that are used in ECP.
Mode of action
Although ECP has been in clinical use for more than 25 years
and is widely used for a variety of clinical entities, the mode of
action remains elusive. The original focus included clinical stud-
ies and the identification of new indications – as the initial regi-
men was (by chance) successful, there was lack of incentive to
study the mechanism of action to optimize therapy. Indeed,
doses and treatment intervals in current use are more or less the
same as those used in the 1980s. Early studies indicated that ECP
induced apoptosis in lymphocytes, which in some way contrib-
uted to the therapeutic effect.8,9 More recent studies, most using
animal models despite their clinical limitations, have shown the
mechanism of action of ECP to be primarily attributable to an
immunomodulatory effect – the principal basic mechanisms
comprising modulation of dendritic cells, alteration of the cyto-
kine profile, and induction of particular T-cell subpopulations.10,11
ECP, like psoralen plus UVA (PUVA), induces psoralen-med-
iated DNA crosslinks, which cause apoptosis of lymphoid cells,
particularly natural killer (NK) and T cells.12 The therapeutic
effect of ECP in Sezary syndrome (SS), however, cannot be
explained by depletion of malignant cells, as only a minority of
the entire lymphocyte pool is included in a photopheresis cycle.
Monocytes treated in the same way appear to be more resistant
than lymphocytes to apoptosis, undergoing a differentiation
process within 2 days and expressing surface markers that are
characteristic of immature dendritic cells (CD83, X-11, Alpha-V,
Beta-V, CD1a).13–15 This differentiation appears to be indepen-
dent of psoralen-induced photoactivation, and is mostly driven
by contact of the cells with plastic and other synthetic materials
during passage through the photopheresis system. The apoptotic
lymphocytes are phagocytosed and eliminated upon re-infusion
– this phagocytosis of apoptotic lymphocytes by immature den-
dritic cells, which subsequently undergo maturation and present
antigenic peptides, has been designated transimmunization.16
Indeed, it has been suggested that transimmunization induces an
immune response against lymphoma cells, which might explain
the beneficial effect of ECP in SS.
The ECP-initiated cellular mechanisms of differentiation are
associated with the release of a variety of cytokines. These
Table 1 ECP approaches in current use in adults and children (adapted from Wong and Jacobsohn7).
Methodology Automated Weight limit Cell separator
extracorporeal volumes
Cell separator technology
One-step methods
CELLEX (Therakos)* Yes (double needle) RBC prime needed
if >115% ECV
Variable, dependent on Hct,
blood volume processed,
return bag threshold
(lower than UVAR XTS)
IFC (continuous buffy coat
collection with intermittent
ﬂuid return) (Latham Bowl)
Yes (single needle) RBC prime needed
if >115% ECV
Variable, dependent on Hct,
blood volume processed,
return bag threshold (higher
than double needle method)
CFC (Latham Bowl)
UVAR XTS (Therakos) Yes (single needle) >40 kg (need to
satisfy ECV limits)
Variable, dependent on Hct,
number of cycles and
bowl size (225 or 125 mL)
IFC (Latham Bowl)
Two-step methods**
COBE Spectra (Terumo BCT)
and UVA irradiator
Yes (only cell
separation)
None 282 mL (MNC procedure,
Version 4.7); 165 mL (AutoPBSC
procedure, Version 6.0)
CFC
Mini-buffy coat and UVA irradiator No Smaller children None, but limited to 5–8 mL/kg
whole blood draw
Standard manual buffy
centrifugation technique
Three step methods†
COBE Spectra (Terumo BCT) &
UVAR XTS (Therakos)
Yes (only cell
separation)
None See above for MNC and
AutoPBSC procedure
CFC
*Suitable for low body weight patients.
**Only cell separation is automated, while the UVA irradiator is operated manually. Other dedicated continuous or intermittent cell separators may also
be used such as Amicus (Fenwal, MNC kit), AS104 (Fresnius Kabi) which has extracorporeal volumes of 163 and 175 mL respectively.
†Three-step methods involve standard mononuclear cell collection using dedicated continuous cell separators, followed by red blood cell priming of
UVAR-XTS instrument and photoactivation treatment of the 8-methoxypsoralen treated mononuclear cells within the UVAR-XTS instrument after pro-
gramming the instrument that the last ECP cycle has occurred.
CFC, continuous ﬂow centrifugation; ECV, extracorporeal cell volume; Hct, haematocrit; IFC, intermittent ﬂow centrifugation; MNC, mononuclear cell;
RBC, red blood cell.
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include tumour necrosis factor (TNF)-a and interleukin (IL)-6,
which induce the activation of CD36-positive macrophages.17
Indeed, it should be pointed out that long-term immunological
alterations can be induced by continuous ECP. Depending on its
severity, CTCL is associated with an imbalance in the Th1/Th2
immune response, which includes increased release of IL-4 and
IL-5, reduced activity of NK cells, and reduced cytotoxicity of
CD8-positive T cells. In a study of patients with early-stage
CTCL (stage IB) undergoing ECP for 1 year, Di Renzo and col-
leagues observed not only an increase in CD36-positive mono-
cytes in the peripheral blood but also a change in the cytokine
reaction profile of peripheral blood lymphocytes upon stimula-
tion with phytohaemagglutinin.18 This implies that ECP reverses
the pathologic shift towards a Th2 immune response in CTCL
patients and restores the Th1/Th2 balance. In addition, anti-
inflammatory cytokines appear to be induced by ECP, whereas
pro-inflammatory cytokines are reduced.19
Over time, ECP has been shown to be beneficial not only in
patients with CTCL but also in those with GVHD, transplant
rejection and various autoimmune diseases. The above-men-
tioned findings, however, cannot explain the effects of ECP in
these patients and, as these conditions respond to immunosup-
pressive therapies, it was surmised that ECP might also exert
inhibitory effects on the immune system. Furthermore, in
patients with GVHD, ECP was shown to induce IL-10 via modu-
lation of arginine metabolism.20 In contrast to immunosuppres-
sive therapy, ECP is not associated with any major side-effects,
including opportunistic infections. It has been postulated that
the therapeutic effect of ECP operates presumably via the induc-
tion of regulatory T (Treg)-cells, without causing general immu-
nosuppression. Using a murine contact hypersensitivity model,
Maeda and colleagues demonstrated the induction of Treg-cells
by an ‘ECP-like’ procedure (intravenous injection of leucocytes
exposed to 8-MOP and UVA in vitro).21 Treg-cells induced in
this way appeared similar to UVB-induced Treg-cells, which
express CD4, CD25, CTLA-4 and the transcription factor Foxp3,
and which suppress the activity of other lymphocytes.22 Further-
more, the release of IL-10 appears to be involved in this
Table 2 European CE mark and FDA approval status of the ‘one-step’, closed photopheresis systems and the various cell separation
and drug photo activation systems used in the ‘two step’ photopheresis procedures.
Company European CE mark FDA approval
Closed photopheresis systems
CELLEX* Therakos √For photopheresis √For photopheresis
UVAR XTS Therakos √For photopheresis √For photopheresis
Tubing set (XTS and CELLEX) Therakos √For photopheresis √For photopheresis
Uvadex Therakos √For photopheresis √For photopheresis
Cell separation system (standard apheresis device)
Spectra Optia Terumo BCT √For therapeutic plasma
exchange and white blood
cell collection (leucocytes
and polymorphonuclear cells)
√For therapeutic plasma
exchange and leucocytes
collection
Cobe Spectra Terumo BCT √For therapeutic plasma
exchange and white blood
cell collection (leucocytes
and polymorphonuclear cells)
√Automated blood cell separator,
approved for therapeutic plasma
exchange and white blood cell
collection (leucocytes and
polymorphonuclear cells)
Com.Tec Fresenius Kabi √For therapeutic plasma
exchange and white blood
cell collection (leucocytes and
polymorphonuclear cells)
√For therapeutic plasma exchange
and white blood cell collection
(leucocytes and polymorphonuclear cells)
MCS plus Haemonetics √For therapeutic plasma exchange
and leucocytes collection
√For therapeutic plasma exchange
and leucocytes collection
AMICUS Fenwal √For therapeutic plasma exchange
and leucocytes collection
√For therapeutic plasma exchange
and leucocytes collection
Drug photoactivation system
PUVA light system Macopharma CE marked (indicated to treat psoriasis,
not dedicated to ECP)
No
MACOGENIC Macopharma UVA illumination machine CE 0459 No
MACOGENIC G2 Macopharma UVA illumination machine CE 0459 No
XUV bag Macopharma UVA illumination machine CE 0459 No
8-MOP Macopharma AMM PTA 07.10.109 (indicated for nuclear
cell photosensibilisation)
No
UVA PIT system MedTech Solutions Medical device for photoimmune therapy No
*Suitable for low body weight patients.
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process.23 A recent study of 46 patients with chronic GVHD
(cGVHD) measured serum B-cell activating factor (BAFF) and
found that BAFF levels at 1 month after ECP predicted 3- and 6-
month skin response, with levels <4 ng/mL being associated
with a significant skin improvement.24
The manifestation of acute GVHD (aGVHD) in patients with
allogeneic grafts can be associated with a low number of Treg-
cells,25–28 and induction of T cells with regulatory properties fol-
lowing ECP has been confirmed in a murine GVHD model.25
Hence, several research groups have studied the effect of ECP on
the number of Treg-cells. In the majority of both CTCL and
GVHD patients, an increase in Treg-cells was observed, as well
as an enhanced suppressive activity.29–34 This could explain, at
least partially, the beneficial effect of ECP in both GVHD and
autoimmune diseases, although how this relates to the positive
effect of ECP in patients with CTCL remains unknown. In
patients with SS, however, reduced numbers of Treg-cells have
been observed,35,36 and their suppressive function appears to be
impaired.37 This has led to speculation on whether Treg-cells
have the capacity to suppress CD4-positive tumour cells in
patients with SS, and this remains to be determined.
A recent study showed that ECP slightly increased or stabi-
lized the number of peripheral CD4+CD25+FoxP3+ Treg-cell
counts in lung transplant recipients who showed functional sta-
bilization.38 Overall, the re-infusion of the treated leucocytes
mediated a specific suppression of both the humoral and cellular
rejection response, and thereby induced tolerance of the allo-
graft, thus prolonging the survival of transplanted tissues and
organs. The mechanism by which ECP counteracts cardiac rejec-
tion was studied using a murine model of ECP.38 Splenocytes
exposed to 8-MOP and UVA were injected into syngeneic mice
both before and after heterotopic cardiac allograft transplant.
None of the mice received immunosuppressive agents. The
treatment group showed extended cardiac allograft survival and
increased levels of FoxP3-expressing CD4+CD25+ T cells when
compared with controls. The authors concluded that the murine
model of ECP extends graft survival in fully histo-incompatible
strain combinations with no immunosuppression.38
In Crohn’s disease, activation of the counterbalancing regula-
tory response induced by Treg-cells directed against the hyperac-
tive adaptive arm of the immune system could compromise
general functionality against pathogenic danger signals. Re-infu-
sion of ECP-generated apoptotic leucocytes back into the patient
are hypothesized to generate a tolerogenic response via Treg-
cells; indeed, re-circulation of DNA-adduct-positive cells to the
intestinal mucosa has been described following ECP.23,39 Murine
models of inflammatory bowel disease have provided informa-
tion on the potential therapeutic role of Treg-cells in overcom-
ing the disease in humans.40
In the only randomized, double-blind, placebo-controlled
trial of ECP in children with type 1 diabetes (T1D), the effects of
ECP on the immune system were also studied.41 There were no
major effects of ECP on lymphocyte populations. However, in
the placebo group, the proportions of activated CD4+ and CD8+
cells increased over time, whereas such changes were not seen in
the ECP-treated group. These findings probably reflect an activa-
tion of lymphocytes as part of the natural course of T1D and
that ECP may have some suppressant effects, preventing lym-
phocyte activation.42 ECP produced cytokine changes reflecting
a Th2-like response.43 Placebo-treated patients showed reduced
T-cell-associated activity, which seemed to be counteracted by
ECP, whereas ECP-treated patients showed preserved T-cell
activity. These data indicate that ECP acts to maintain Treg-cell-
associated activity in recent-onset T1D.44
Although partial aspects of the mode of action of ECP, such
as the induction of Treg-cells, are quite clear, we are still far away
from a complete understanding of how ECP works. The recent
establishment of animal models will give the opportunity to
modify the ECP procedure with regard to the number of cycles,
doses of 8-MOP and UVA, and the number of cells infused, with
the ultimate aim of optimizing the regimens that are currently
used. In addition, greater understanding of the mechanism of
action will finally enable this therapy to be directed towards
those patients who could most benefit from it.
Methodology
Guidelines on the use of ECP were identified through a literature
search, an internet search of relevant medical databases and a
search of relevant professional bodies, as well as expert opinion
on the appropriate use of ECP based on ‘best medical practices’.
The literature evaluated in the existing guidelines, brought up to
date with more recently published data, serves as the basis for
the present set of guidelines.
ECP is not widely available and is generally used for severe
refractory disease courses, or in situations in which other thera-
pies have been tried and have failed. Therefore, the use of this
treatment is not generally based on data from controlled and
randomized clinical trials, which are usually required for evi-
dence-based medicine, but on multiple small-cohort or case–
control studies. Double-blinded trials are difficult, and sham
photopheresis may be unethical in patients with severe disease.
The guidelines presented here were drawn up to present the
indications for which ECP is currently considered as effective, as
well as other indications where studies with ECP have shown
promising results. For the major indications, namely CTCL and
GVHD, the recommendations were developed by a group of
experts who are leaders in the development of specific guidelines
in these disease areas. For minor indications, expert committees
were brought together to examine the available evidence and to
make recommendations based on this. The aim was to answer
the following questions for each clinical condition:
1 Which diseases are indicated for treatment with ECP?
2 Are there currently any guidelines/consensus statements on
ECP in this indication?
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3 Which patients should be considered for ECP treatment?
4 What is the optimal treatment schedule and how long should
ECP treatment be continued?
5 How is therapeutic efficacy assessed?
The recommendations were developed and discussed for con-
sensus decision at a number of consensus meetings where the
authors and experts were present for reaching consensus agree-
ments (Gothenburg, Sweden, 8 October 2010; Minden, Ger-
many, 24 September 2011; Lisbon, Portugal, 21 October 2011;
Geneva, Switzerland, 31 March 2012; Verona, Italy, 8 June 2012
and Prague, Czech Republic, 28 September 2012). The docu-
ment was circulated among all members of the Guidelines Sub-
committee and then the Guidelines Committee for final
approval following the European Dermatology Forum (EDF)
standard operating procedures.
Cutaneous T-cell lymphoma
CTCL describes a heterogeneous group of rare lymphoprolifera-
tive disorders, which are characterized by the accumulation of
malignant T-cell clones that home to the skin.45 The most com-
mon variants are mycosis fungoides (MF), which accounts for
about 60% of CTCL cases, and SS, which accounts for 5% of
cases. MF is characterized by the presence of a clonal T-cell pop-
ulation in the cutaneous environment and, in the early stages of
the disease, presents as scaly patches or plaques, which may
resemble eczema or psoriasis in appearance and are often associ-
ated with pruritus. As the disease progresses, patients may expe-
rience the growth of nodular lesions and large tumours, also
with severe pruritus, which may ulcerate and result in chronic
septicaemia, thrombosis and pain. SS is the ‘leukaemic’ form of
CTCL, in which the dominant T-cell population also circulates
in the peripheral blood and may affect internal organs such as
the lungs and spleen. MF/SS is classified into clinical stages from
IA (the earliest stage) to IVB according to the degree of skin,
lymph node, peripheral blood and visceral organ involvement.46
Curative therapies are not available and treatment is usually
directed towards palliation and the induction of long-term
remissions. The aim was to reduce or clear skin lesions, includ-
ing tumours and reduce pruritus, thereby providing symptom
relief and improving patient quality of life.45 In the early stages
of MF, treatment usually involves skin-directed therapies, such
as topical corticosteroids, topical chemotherapy (nitrogen mus-
tard or bis-chloronitrosourea) or phototherapy (narrow-band
UVB or PUVA). Systemic therapies, including chemotherapy
and biological response modifiers [such as interferon (IFN)-a
and bexarotene] are used if the disease progresses, or for those
who present with more advanced-stage disease, often in combi-
nation with skin-directed therapies.47
PUVA, in which patients take an oral formulation of 8-MOP
to induce photoactivation followed by exposure of their skin to
UVA radiation, is a widely used and effective skin-directed ther-
apy for early-stage, skin-localized CTCL,47 which can produce
relatively long-lived remissions. It is, however, associated with
short-term side-effects of oral psoralen intake and possible long-
term complications such as photosensitivity and the potential
for development of skin cancer.3 ECP has enabled the safety pro-
file of PUVA to be improved, avoiding the potential complica-
tions associated with long-term skin exposure to UVA. It also
means that the benefits of therapy can be extended beyond the
treatment of patients with predominantly early disease to patient
populations with more advanced disease and the presence of a
circulating malignant clone in their peripheral blood.3
Many studies have demonstrated that ECP is of significant
value in the treatment of CTCL. However, because of the rarity
of the disease and specialized delivery of therapy, there are no
prospective, placebo-controlled, randomized clinical trials that
evaluate the impact of treatment on survival, and any compari-
sons made are usually with ‘historical controls’. The initial study
of ECP in patients with CTCL resistant to other treatments was
reported by Edelson and colleagues in 1987 and showed it to be
a promising therapy.5 Among 37 patients, 27 (73%) responded
to treatment, with an average 64% decrease in cutaneous
involvement; nine of these patients had a complete response
(CR). Data from this study have recently been re-analysed using
modern criteria, resulting in a skin overall response rate of 74%,
with 33% of patients achieving ≥50% partial skin response and
41% achieving ≥90% improvement.48 An update on the overall
survival (OS) of these patients was also provided, which was
9.2 years from diagnosis and 6.6 years from initiation of ECP.
Since 1987, numerous studies have been conducted. A meta-
analysis of 19 studies in more than 400 patients at all stages of
CTCL reported a combined overall response (OR) rate of 56%
with ECP used as monotherapy and 56% when used in combina-
tion with other agents, of which 15% and 18%, respectively,
were CRs.49 For erythrodermic disease, the OR rate was 58%
and the CR rate was 15%. Importantly, ECP was effective in SS,
showing an OR rate of 43%, with 10% CRs. Table 3 (adapted
from the UK consensus statement on the use of ECP for the
treatment of CTCL and GVHD50) provides a summary of the
published response rates with ECP in the treatment of CTCL
from 1987 to 2011. Based on the 30 separate studies in 689
patients published from 1987 to mid 2007 that were analysed in
the UK consensus statement, the mean OR rate in the studies
that reported these data was 63% (range 33–100%), and
response rates were generally higher among patients with ery-
throdermic CTCL.50 The CR rate, where recorded, ranged from
0% to 62% (mean 20%). More recent studies published from
late 2007 to 201151–57 report OR rates ranging from 42% to
80%, with CR rates ranging from 0% to 30%.
It is clear that ECP is beneficial in the treatment of CTCL, but
it is also apparent that there are considerable differences in
response rates between centres. Such differences may relate to a
number of factors, including differences in patient selection,
stage of disease, prior treatments received, ECP protocol used,
© 2013 The Authors. Journal of the European Academy of Dermatology and Venereology
published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.JEADV 2014, 28 (Suppl. 1), 1–37
6 Knobler et al.
duration of ECP and the definition of response that is used.50
Similar considerations apply to studies reporting survival in
patients with CTCL treated with ECP. Variable median survival
data have been reported for SS, ranging from 30 months58 to
60 months,59 which probably reflects the use of different diag-
nostic criteria. Much longer median survival for CTCL treated
with ECP has been reported, but not all patients in the studies
had erythrodermic disease or they had received other therapies
in combination.60,61
The studies listed in Table 3 include ECP used as monothera-
py and in combination with other therapies. Such combination
therapies have been investigated as a way to further improve
response rates, particularly in patients with a high tumour bur-
den. The largest series of CTCL patients treated by ECP was
Table 3 Summary of studies using extracorporeal photopheresis as monotherapy or in combination with other therapies for the treat-
ment of cutaneous T-cell lymphoma (adapted from Scarisbrick et al. 2008 50).
Patients (n) OR CR PR MR
Edelson et al.5 37
(erythrodermic 29)
73% (27/37)
83% (24/29)
24% (9/37) 35% (13/37) 14% (5/37)
Heald et al.59 32
(erythrodermic 22)
NK
86% (19/22) 23% (5/22) 45% (10/22) 18% (4/22)
Nagatani et al.289 7 43% (3/7) NK NK
Zic et al.290 20 55% (11/20) 25% (5/20) 30% (6/20)
Koh et al.291 34 (erythrodermic 31) 53% (18/34) 15% (5/34) 38% (13/34)
Prinz et al.292 17 (erythrodermic 3) 71% (12/17) 0% (0/17) 41% (7/17) 29% (5/17)
Duvic et al.293 34 (erythrodermic 28) 50% (17/34) 18% (6/34) 32% (11/34)
Gottlieb et al.60 28 (erythrodermic NK) 71% (20/28) 25% (7/28) 46% (13/28)
Stevens et al.294 17 (erythrodermic) 53% (9/17) 29% (5/17) 24% (4/17)
Zic et al.61 20 (erythrodermic 3) 50% (10/20) 25% (5/20) 25% (5/20)
Konstantinow and Balda295 12
(erythrodermic 6)
67% (8/12)
50% (3/6)
8% (1/12)
0% (0/6)
42% (5/12)
50% (3/6)
17% (2/12)
Miracco et al.296 7 86% (6/7) 14% (1/7) 71% (5/7)
Russell-Jones et al.297 19 (erythrodermic) 53% (10/19) 16% (3/19) 37% (7/19)*
Vonderheid et al.298 36
(erythrodermic 29)
33% (12/36)
31% (9/29)
14% (5/36)
10% (3/29)
19% (7/36)
21% (6/29)
Zouboulis et al.299 20 65% (13/20) NK NK
Jiang et al.300 25 (erythrodermic) 80% (20/25) 20% (5/25) 60% (15/25)
Bisaccia et al.65 37 54% (20/37) 14% (5/37) 41% (15/37)
Crovetti et al.301 30
(erythrodermic 9)
73% (22/30)
66% (6/9)
33% (10/30)
33% (3/9)
40% (12/30)
33% (3/9)
Wollina et al.302 20 65% (13/20) 50% (10/20) 15% (3/20)
Wollina et al.64 14 50% (7/14) 29% (4/14) 21% (3/14)
Bouwhuis et al.303 55 SS 80% (44/55) 62% (34/55) 18% (10/55)
Knobler et al.304 20
(erythrodermic 13)
50% (10/20)
85% (11/13)
15% (3/20)
15% (2/13) 54% (7/13) 15% (2/13)
Suchin et al.62 47 79% (37/47) 26% (12/47) 53% (25/47)
Quaglino et al.305 19 63% (12/19) NK NK
De Misa et al.306 10 (advanced SS) 60% (6/10) 10% (1/10)
Rao et al.307 16 44% (7/16) NK NK
Gasova et al.308 8 (2 with CTCL) 100% (2/2) NK NK
Tsirigotis et al.51 5 (SS 2) 80% (4/5) 20% (1/5) 60% (3/5)
Arulogun et al.52 13 (all SS; 12 erythrodermic) 62% (8/13) 15% (2/13) 46% (6/13)
Booken et al.53 12 (all SS) 33% (4/12) 0% (0/12) 33% (4/12)
McGirt et al.54 21 (18 erythrodermic) 57% (12/21) 14% (3/21) 19% (4/21) 24% (5/21)
Quaglino et al.57 48 (all erythrodermic; 12 MF, 36 SS) 60% (29/48) 13% (6/48) 48% (23/48)
Raphael et al.56 98 (all erythrodermic) 74% (73/98) 30% (29/98) 45% (44/98)
Talpur et al.55 19 (all early-stage MF) 63% (12/19) 11% (2/19) 53% (10/19)
*Combined PR and MR.
CR, complete response; MF, mycosis fungoides; MR, minor response (>25% improvement in skin scores); NK, not known; OR, overall response (CR +
PR); PR, partial response (>50% improvement in skin scores); SS, Sezary syndrome.
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recently published by Rook and colleagues in the USA, who
reported their experience over a 25-year period in 98 erythroder-
mic CTCL patients treated with at least 3 months of ECP and
one or more systemic immunostimulatory agents.56 A clinically
significant improvement was obtained in 75% of patients with
this multimodality therapy, with 30% having a CR.
Previously, Suchin and colleagues reported on 47 patients who
had received at least 6 cycles of ECP: 68% had stage III or IV CTCL
and 89% had circulating malignant T cells.62 Thirty-one patients
received treatment with ECP and one or more other systemic
agents, including IFN-a, IFN-c, granulocyte–macrophage colony-
stimulating factor (GM-CSF; sargramostim) or systemic retinoids,
for 3 months or more. Overall, 79% of patients responded to ther-
apy, with 26% having a CR. Among patients receiving combina-
tion therapy, 84% achieved a response, with 20% having a CR,
whereas the OR rate with ECP monotherapy was 74%, of which
38% were CRs. The median survival was 74 months with combi-
nation therapy vs. 66 months for ECP monotherapy, although the
difference was not statistically significant.
A prospective observational study in 48 patients with erythro-
dermic CTCL (36 with SS) reported a response rate of 58% with
ECP alone, compared with 64% with combination therapy in
patients with more adverse prognostic factors.57 Similarly, Duvic
and colleagues reported a slightly higher response rate among 32
patients treated with ECP in combination with IFN-a, bexaro-
tene or GM-CSF compared with 54 who had received ECP
monotherapy (OR > 50% in 56% vs. 43% respectively).63 A
number of other studies with ECP plus IFN-a have been pub-
lished that report an increased response rate compared with ECP
monotherapy.60,64,65 However, none of these studies was con-
trolled or randomized, making it difficult to assess how much of
the clinical benefit was due to IFN-a and how much to ECP, and
what synergistic effects can be obtained.
ECP has also been used in combination with total skin elec-
tron beam (TSEB) therapy. A retrospective study of 44 patients
with erythrodermic MF/SS treated with TSEB with or without
ECP reported an overall CR of 73% with a 3-year disease-free
survival of 63%.66 Among those receiving combined TSEB and
ECP, the 3-year disease-free survival was 81% compared with
49% with TSEB alone. On the basis of these data, further studies
with the TSEB and ECP combination are warranted.
Most of the studies with ECP in CTCL have primarily
included patients with advanced stages of the disease. Guidelines
recommend ECP as first-line systematic therapy for erythroder-
mic MF and SS.47,50,67–69 Its use in early stages of CTCL is con-
troversial but warrants further investigation. A literature review
of data from 16 studies with ECP or ECP plus adjuvant therapy
from 1987 to 2007, which included a total of 124 patients with
early-stage (stage IA, IB, IIA) CTCL, found that the response
rates ranged from 33% to 88% if ECP was used as monotherapy
and from 50% to 60% with ECP plus adjuvant therapy.70 Fur-
thermore, many early-stage patients treated with ECP achieved
long-lasting regression of disease. In a recent study, 19 patients
with early-stage MF were treated with ECP on two consecutive
days every month for 6 months.55 Patients with a partial
response (PR) continued with ECP alone for 6 months, whereas
non-responders could receive additional therapy with oral
bexarotene and/or IFN-a. The OR rate for ECP alone was 42%
(8/19, including 1 CR; 7 PR), with an overall duration of
response of 6.5 (range 1–48) months. Seven patients with stable
disease at 3 months received additional bexarotene and/or
IFN-a and four (57%) responded. For all 19 patients, the OR
rate was 63% (2 CR, 10 PR). Most guidelines do not indicate use
of ECP in early stage disease, but the National Comprehensive
Cancer Network (NCCN) Guidelines recommend ECP in those
patients with stage IA, IB and IIA refractory disease.69
In summary, for patients with advanced CTCL (such as those
with erythroderma or the presence of peripheral blood involve-
ment), which are typically resistant to treatment and weighted
by a poor prognosis, ECP, either as monotherapy or combined
with other immunotherapies, offers good treatment efficacy and
the possibility of prolonged survival. Given the very low side
effect profile of ECP compared with other therapies and its dem-
onstrated efficacy in later-stage CTCL, this treatment modality is
possibly also beneficial in earlier stages of the disease, as recently
suggested,55 although further studies that focus on this patient
population are needed. There is, however, inter-patient variabil-
ity in the response to ECP in CTCL, so attempts have been made
to characterize those patients who are most likely to be respond-
ers. The prognostic factors that have been identified include the
following50,70,71:
• short duration of disease, preferably <2 years;
• absence of bulky lymphadenopathy or major internal organ
involvement;
• white blood cell count <20 000 mm3;
• presence of a discrete number of Sezary cells (10–20% of
mononuclear cells);
• natural killer cell activity close to normal;
• cytotoxic T lymphocytes close to normal (CD8+ > 15%);
• absence of prior intensive chemotherapy; and
• plaque stage disease not covering more than 10–15% of
total skin surface.
Although these criteria are useful in identifying the likely best
responders to ECP, they are not absolute, and some patients
who fall outside these criteria will also respond.71 A critical fac-
tor for success is that the patient must be able to mount an
immune response against the malignant cells that have passed
through the photoactivating device.72,73
Existing clinical guidelines
Several professional organizations have produced guidelines on
the management of CTCL and the use of ECP.
In the European Organization for Research and Treatment of
Cancer (EORTC) consensus recommendations for the treatment
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of MF/SS (published in 2006),47 ECP was recommended for the
first-line treatment of MF stage III and for first-line treatment of
SS, with a strength of recommendation of C (on a scale from A
to D). In MF, the level of evidence was rated as 4 (evidence from
case series, poor-quality cohort or case–control studies) and in
SS as 2b (evidence from individual cohort study or poor-quality,
randomized, controlled trial). Although not a recommendation,
it was mentioned that the usual ECP treatment schedule was two
successive days every 4 weeks, continued for up to 6 months,
followed by maintenance therapy tailored according to disease
course and severity.
The UK Photopheresis Expert Group consensus statement
on the use of ECP50 is a comprehensive document published in
2008, which, after reviewing the literature, recommended that
ECP should be considered for the treatment of patients with
CTCL who fulfil both of the major criteria of erythroderma
and stage III or IVA CTCL (histology consistent with CTCL),
as well as one of the minor criteria: circulating clonal disease
(circulating T-cell clone by polymerase chain reaction or South-
ern blot analysis); evidence of circulating Sezary cells (>10% of
circulating lymphocytes); CD4/CD8 ratio >10. The recom-
mended treatment cycle was one cycle (i.e. two consecutive
days) every 2–4 weeks (to be given more frequently in symp-
tomatic patients and in those with a high peripheral blood
tumour burden). Treatment should be tapered at maximal
response or greater to one cycle every 6–12 weeks before stop-
ping. Guidance was provided on monitoring treatment, and
assessments at 3-monthly intervals were recommended, to
allow non-responders to be offered combination or alternative
therapy and to ensure that ECP treatment was not prolonged
in detriment to their health, and to avoid ECP being given
alone for more than 6 months in patients with responses of less
than 50%.
The British Photodermatology Group and UK Skin Lym-
phoma Group published a report in 2006 on evidence-based
practice of ECP based on data from 1987 to 2001,74 which
looked at the use of ECP in a variety of conditions. They con-
cluded that there was: ‘fair’ evidence that ECP has clinical benefit
in erythrodermic MF/SS (stage III/IVA/B1/0), with a strength of
recommendation of B (on a scale from A to E), based on level
II-i evidence (i.e. from well-designed controlled trials without
randomization); ‘fair’ evidence to support the use of TSEB with
ECP for erythrodermic MF/SS [strength of recommendation B,
quality of evidence II-ii (well-designed cohort or case–control
studies)]; and poor evidence to support the use of IFN-a plus
ECP for erythrodermic MF/SS (strength of recommendation C,
quality of evidence II-ii). The authors described a typical proto-
col of two ECP treatments on two consecutive days per month,
continued for up to 6 months, followed by tapering or mainte-
nance treatment in those patients who have responded – the fre-
quency of treatment can be increased to fortnightly in poor
responders, or ECP can be combined with other therapeutic
agents such as IFN-a. Recommended patient assessments and
appropriate efficacy parameters were also listed.
The National Cancer Institute in the USA guidance on treat-
ment of MF and SS68 listed appropriate treatments at each
CTCL disease stage. ECP was included as an option for the
treatment of stage III MF/SS and, either alone or with TSEB,
for the treatment of stage IV MF/SS. For patients with recur-
rent MF/SS, it was noted that ECP has produced tumour
regression in those who are resistant to other therapies. No
information was given on the appropriate monitoring of ther-
apy or of outcomes.
The NCCN clinical guidelines on MF/SS (2012) state that
their recommendations are all based on category 2A evidence
(lower level evidence but with NCCN consensus). ECP was rec-
ommended as first line for stage IV SS, alone or in combination
with interferon or bexarotene. ECP was also recommended in
relapsed or refractory stage III disease and in IA, IB–IIA disease
refractory to skin-directed therapy.69
The United States Cutaneous Lymphoma Consortium (US-
CLC) reviewed the therapeutic options for SS.75 ECP was recom-
mended as a category A systemic monotherapy, based on level
II-2 evidence (i.e. obtained from at least one prospective, well-
designed cohort or case–control study, preferably from more
than one centre or research group). In addition, recommended
category A combination therapies included TSEB plus ECP alone
or in combination with IFN-a, IFN-c or bexarotene, and ECP
plus bexarotene, IFN-a, IFN-c or low-dose methotrexate singly
or in combination.
The NORth Trent COMmissioners (NORCOM) policy on
ECP for cancer and disease (reviewed in 2008)76 was developed
to provide guidance to five UK Primary Care Trusts on when
ECP therapy should be funded. It concluded that, based on case
series studies alone (i.e. lower quality evidence than randomized
controlled trials), the evidence supports the use of ECP for ery-
throdermic MF/SS. They recommended that, to be eligible for
treatment, patients with CTCL should fulfil all the following cri-
teria: erythroderma, biopsy-proven diagnosis of CTCL, evidence
of circulating clonal disease and evidence of circulating Sezary
cells (10% of lymphocytes present). The recommended treat-
ment was two consecutive days of ECP per month for a mini-
mum of 6 months. Recommendations were also provided on
monitoring of therapy, response assessment criteria and tapering
of treatment in responders.
Finally, the Association of the Scientific Medical Societies of
Germany recently provided guidance on the staging, assessment,
diagnosis and therapy of cutaneous lymphomas.77 ECP was rec-
ommended as first-line treatment for erythrodermic MF stage
III and for SS. The guidelines stated that ECP could be combined
with IFN-a, methotrexate, bexarotene or PUVA, and they also
commented on the good safety profile of ECP. No rating of the
grade of recommendation or level of evidence was given, and no
information was provided on how the guidelines were prepared.
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Recommendations
Patient selection ECP should be considered as first-line ther-
apy for the following CTCL patients.
• Erythrodermic stage IIIA or IIIB (i.e. with B0 or B1 score
according to the revised International Society for Cutaneous
Lymphomas [ISCL]/EORTC classification).46
Even though a series of papers (see the recent study by Tal-
pur et al.55) have suggested that there is a potential benefit
of ECP in patients with early-stage disease (stage IA, IB,
IIA), the consensus decision was that this indication should
be considered only for clinical trial purposes, as a variety of
other safe, effective and easily accessible treatment options
are available for use at this stage.
• Stage IVA1 (i.e. patients with B2 score) and a T score of T1,
T2 or T4.
• Stage IVA2 (i.e. patients with N3 score) and a T score of T4.
Treatment schedule
• Initial recommended schedule should be one cycle (i.e. two
consecutive days) every 2 weeks for the first 3 months, then
once monthly or every 3 weeks. However, there is no clear
optimal therapy, and other published guidelines have rec-
ommended one cycle every 2–4 weeks, followed by tapering
after maximum response.50
There are no controlled data in the literature that clearly
support higher clinical activity associated with more fre-
quent ECP courses. On the basis of clinical experience, it
was recognized that an initial increased frequency of treat-
ment courses could give a potentially significant benefit,
particularly in patients with strong subjective symptoms
(itchiness) and those with B2 score. However, based on
patient compliance, a standard monthly treatment could
also be performed, according to the policies and possibilities
at each centre.
• Treatment should be continued for a time period of not less
than 6 months, and ranging between 6 and 12 months to
evaluate for a positive response.
• At maximal response, treatment should be slowly tapered to
one treatment every 4–8 weeks for maintenance therapy.
• In patients with a response or disease stabilization and good
quality of life, ECP treatment should not be stopped and
should be prolonged for even more than 2 years, with a
progressive extension of treatment intervals up to 8 weeks.
• Patients who do not respond to ECP as first-line therapy
should be considered for combination therapies (i.e. ECP
plus other drugs).
• The agents that should be associated with ECP on the basis
of their known immunomodulatory mechanisms are IFN
and/or bexarotene.
Skin care and topical medications need to be included from
the start of ECP. In addition, topical steroids applied on
selected parts of the body skin surface are allowed in associ-
ation with ECP, particularly in patients with strong subjec-
tive symptoms.
In patients with a frank ‘leukaemic’ involvement with high
white blood cell counts (i.e. >20 000 mm3), cytoreductive
treatment (debulking chemotherapy or alemtuzumab) can
be performed before ECP to decrease the extent of periph-
eral blood involvement. Also, local radiotherapy can be per-
formed either before or during ECP to treat localized
infiltrated lesions. While the association of ECP with his-
tone deacetylase inhibitors appears potentially useful, at
present there are no published data available to support this
combination.
• Systemic concurrent therapies can be initiated at any time
point at the discretion of each centre; however, it is sug-
gested to wait for at least 3 months of ECP monotherapy
before starting an associated drug. If patients are already
on other therapies (bexarotene and/or IFN), then ECP
can be added without the withdrawal of the previous
treatment.
Response assessment
• Response assessment should be performed every 3 months
and made on the basis of the ISCL/USCLC/EORTC consen-
sus statement.78 It is recommended to wait for at least
6 months of treatment before concluding that ECP is not
effective. Based on clinical experience, responses usually do
not develop early and can also be observed a considerable
period of time after starting ECP. It was agreed that the
minimum time for evaluation of response to ECP should be
after at least 6 months of treatment before it is concluded
that ECP is not effective.
• In the presence of a CR, treatment should not be stopped
and prolonged for a long period of time, with a progressive
extension of treatment intervals up to 8 weeks.
• In the presence of PR/stable disease, it is suggested to evalu-
ate for combination treatments or to increase the frequency
of treatments.
• In the presence of progressive disease, it is suggested to eval-
uate for combination treatments, to increase the frequency
of treatments, or to stop ECP in favour of alternative anti-
CTCL therapy.
Chronic graft-versus-host disease
cGVHD is a serious complication of allogeneic haematopoietic
stem cell transplantation (HSCT), associated with substantial
morbidity and mortality, mainly due to infectious complica-
tions.79–81 First-line therapy of cGVHD consists of corticoster-
oids,82–84 whereas many therapeutic options have been reported
for salvage therapy.85,86 However, no single class of immunosup-
pressive agent has consistently achieved a steroid-sparing effect
in patients with cGVHD.
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ECP represents a frequently used therapeutic approach for the
treatment of cGVHD. Recently, Martin and colleagues, perform-
ing a comprehensive review of both retrospective and prospec-
tive trials of cGVHD therapy, reported on 60 studies evaluating
17 different agents.86 Interestingly, ECP was the most frequently
studied therapy. Tables 4 87–98 and 599–108 provide a summary of
studies with ECP in paediatric and adult patients with cGVHD.
Owsianowski and colleagues reported the first use of ECP in
cGVHD in 1994,109 and it is now a widely recognized second-
line therapy for cGVHD patients failing on corticosteroids.85,110
The safety profile of ECP is excellent, with minimal side-effects
and no long-term complications, particularly in comparison
with other immunosuppressive therapies currently available for
cGVHD (including mycophenolate mofetil, tacrolimus, inhibi-
tors of the mammalian target of rapamycin, hydroxychloroquine
and rituximab), which are known to be associated with increased
organ toxicities, susceptibility for opportunistic infections and
relapse of original disease.85 Most of the evidence on the use of
ECP in cGVHD comes from patients with steroid-refractory dis-
ease and there are very few data currently available for the use of
ECP as a first-line therapy of cGVHD.84 Due to the excellent
safety profile of ECP and frequently reported evidence that the
graft-versus-leukaemia effect seems not to be impaired by ECP,
leading experts in the field of allogeneic HSCT recommend the
use of ECP earlier in the course of cGVHD.95,105,111
Most countries perform ECP in specialized centres and offer
it as a second- or subsequent-line therapy for patients with ste-
roid-refractory, -dependent or -intolerant cGVHD in need of
systemic therapy.85,89,93,98–102,104–107,112–114 Flowers and col-
leagues published the first multicentre, randomized, controlled,
prospective phase II trial of ECP in 95 patients with steroid-
refractory/-dependent/-intolerant cGVHD.106 The primary
efficacy end-point of the study was a blinded quantitative com-
parison of percentage change from baseline in Total Skin Score
(TSS) of 10 body regions at week 12. The median percentage
improvement in TSS at week 12 was 15% for the ECP arm com-
pared with 9% for the control arm, a non-significant difference.
However, significantly more patients in the ECP arm had a com-
plete or partial skin response, as assessed by the clinical investi-
gators (P < 0.001). At week 12, the proportion of patients who
had at least a 50% reduction in steroid dose and at least a 25%
decrease in TSS was 8% in the ECP arm vs. 0% in the control
arm (P = 0.04). A steroid-sparing effect of ECP has also been
reported by other investigators.89,99,102,104,105,108,115 In a subse-
quent prospective clinical study, 29 patients in the control group
Table 4 Summary of studies using extracorporeal photopheresis in paediatric patients with chronic graft-versus-host disease.
Patients (n) CR/PR skin CR/PR liver CR/PR oral Comment
Rossetti et al.87 7 33% (2/6) 100% (1/1) – 50% (2/4) lung CR
Dall’Amico et al.88 4 67% (2/3) – – 67% (2/3) lung improved
Salvaneschi et al.89 14 83% (10/12) 67% (6/9) 67% (8/12) 79% OS
Halle et al.90 8 88% (7/8) 67% (4/6) – 100% OS
Perseghin et al.91 9 88% (7/8) 100% (2/2) 67% (2/3) –
Perutelli et al.92 7 – – – 43% (3/7) CR; 57% (4/7) improved
Messina et al.93 44 56% (20/36) 60% (12/20) – 77% OS
Duzovali et al.94 7 – – – 43% (3/7) improved; 43% (3/7) died
Kanold et al.95 15 75% (9/12) 82% (9/11) 86% (6/7) 67% (10/15) alive
Perseghin et al.96 25 67% (4/6) 67% (4/6) 78% (7/9) 76% (19/25) alive
Gonzales-Vicent et al.97 3 100% (2/2) 100% (2/2) – 100% (3/3) alive
Perotti et al.98 23 96% (22/23) 100% (4/4) 80% (4/5) 83% (19/23) alive at 5 years
CR, complete response; OS, overall survival; PR, partial response.
Table 5 Summary of studies using extracorporeal photopheresis
in adult patients with chronic graft-versus-host disease.
Patients
(n)
CR/
PRskin
CR/
PRliver
CR/
PRoral
OR
Greinix
et al.99
15 80% 70% 100% NK
Apisarnthanarax
et al.100
32 59% 0% NK 56%
Seaton
et al.101
28 48% 32% 21% 36%
Foss
et al.102
25 64% 0% 46% 64%
Rubegni
et al.103
32 81% 77% 92% 69%
Couriel
et al.104
71 57% 71% 78% 61%
Greinix
et al.105
47 93% 84% 95% 83%
Flowers
et al.106
48 40% 29% 53%
Dignan
et al.107
82 92% NK 91% 74%
Greinix
et al.108
29 31% 50% 70% NK
CR, complete response; NK, not known; OR, overall response; PR, partial
response.
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not responding to conventional immunosuppressive treatment
in the initial randomized study were eligible for open-label ECP
in case of progression of cutaneous cGVHD or less than 15%
improvement in the TSS by week 12.108 Besides achieving a com-
plete or partial skin response at week 24 of ECP treatment in
nine patients (31%), response in extracutaneous manifestations
of cGVHD, including oral mucosa, eyes, liver and lung, was
observed in 70%, 47%, 50% and 50% of patients by week 24
respectively.
Organ involvement is a main parameter predicting response
to ECP. Investigators consistently report best responses in skin
(both lichenoid and sclerodermoid), mucous membrane and
liver manifestations of cGVHD. In 2007, Scarisbrick and col-
leagues reviewed 23 individual studies including 633 patients
with cGVHD given ECP between 1987 and 2001.50 The response
rates were recorded according to involved organ. The mean
response rate in cutaneous cGVHD, as reported in 18 studies,
was 68% (range 29–100%), including CRs in some patients. The
mean response rate in patients with hepatic involvement, as
reported in 10 studies, was 63%. The mean response rate in
patients with mucosal involvement, as reported in 9 studies, was
also 63%.
Experience is limited with ECP in other manifestations of
cGVHD, such as lung involvement, with 100 reported patients
achieving a response rate of 51%, including 14 CRs, 20 PRs and
17 improvements.93,104,106,108,116–118 In view of the dismal prog-
nosis of pulmonary cGVHD and the limited therapeutic options
for these patients, results of ECP in pulmonary cGVHD are
encouraging. Nonetheless, the efficacy of ECP in lung manifesta-
tions of cGVHD needs to be determined in prospective studies
with a larger patient cohort. Considering its excellent safety pro-
file, ECP should be administered earlier in the course of cGVHD
to avoid irreversible tissue damage and patient mortality due to
infections during immunodeficiency. ECP has steroid-sparing
properties and may prevent adverse effects from prolonged
immunosuppression.106 Of note, ECP reportedly does not cause
generalized immunosuppression,62 and no increase in infectious
complications has been reported during ECP therapy.99,105,106,119
Many investigators administer ECP in patients with cGVHD
according to the original publication by Edelson and colleagues.5
This consists of two ECP treatments on consecutive days every
2–4 weeks. Typically, therefore, cGVHD has been treated with
4–8 treatments per month, usually for 12–24 weeks.99,105,112
There is little evidence as to the value of increased ECP treat-
ments in this initial phase. In a prospective, phase II study, Foss
and colleagues found no advantage for patients initially treated
with a more intensive weekly schedule compared with those
receiving biweekly treatment.102 Subsequent prolongation of the
interval between ECP treatments is typically performed by many
centres. However, only limited data are currently available on
the advantages and disadvantages of ECP tapering, and thus no
recommendations can be provided. Tapering is influenced in
most series by the ability to reduce concurrent immunosuppres-
sive therapy, regarded as a significant risk factor for infection-
related morbidity and mortality. Progression of cGVHD under
treatment is an indication for discontinuation of ECP, whereas
recurrence of cGVHD during tapering or after discontinuation
of therapy may be controlled by restarting ECP or intensification
of the treatment schedule with a subsequently slower weaning
regime.50
The length of therapy required for individual patients is diffi-
cult to predict from current published literature, in view of the
diversity of treatment schedules applied and the difficulty in
comparing heterogeneous patient populations.89,93,99–
101,104,105,113 Dignan and colleagues reported on 82 patients who
received a bimonthly regimen of two ECP treatments on consec-
utive days (one cycle), which was subsequently tapered to a
monthly regimen depending on response.107 The median dura-
tion of treatment was 330 (range 42–987) days and the median
number of ECP cycles received was 15 (range 1.5–32) cycles.
Eighty-four per cent of patients completed a minimum of
6 months of treatment. Among those receiving immunosuppres-
sive drugs at the start of ECP treatment, 77% had a dose reduc-
tion after 6 months of treatment and 80% had reduced their
steroid dose. However, in the largest retrospective study
published to date, from the MD Anderson Cancer Centre, the
median number of ECP treatments administered was 32 (range
1–259) over a median of 14.5 (range 1–333) weeks.104
Foss and colleagues observed an OR rate of 64%, defined as
response in at least one site of disease, when ECP was given to
25 patients with extensive steroid-refractory cGVHD.102 The
median duration of therapy was 9 (range 3–24) months. In line
with these findings, Greinix and colleagues reported complete
resolution of cutaneous features in 12 of 15 patients (80%) with
steroid-refractory extensive cGVDH who were given ECP for a
median of 12 (range 4–31) months.99 In the recently published
prospective study in 29 patients with steroid-refractory cGVHD,
progressive improvement in the TSS during weeks 16 and 24 of
open-label ECP treatment was observed, suggesting a cumulative
response over time.108 These findings and the higher response
rates reported in other studies with prolonged treatment with
ECP99,100,102 suggest that continuation of ECP beyond 24 weeks
may result in further benefit in patients with longer duration of
cGVHD. Of note, longer treatment duration may also be neces-
sary to obtain best responses to ECP in patients with scleroder-
matous manifestations.99,100,104,120
Survival rates are variable among reports in the literature. Sig-
nificantly improved survival rates and improvements in quality
of life in ECP responders have been reported by Greinix and col-
leagues99,105 and Messina and colleagues.93 In the prospective,
randomized study on steroid-refractory/-dependent/-intolerant
cGVHD patients, ECP treatment was significantly associated with
improved quality of life, demonstrated by a 19% improvement in
the median targeted symptom assessment scores in the ECP arm
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compared with a 3% improvement in the control arm
(P = 0.01).106
Kanold and colleagues treated 15 paediatric patients with ste-
roid-refractory cGVHD, achieving high response rates in those
with cutaneous (75%), hepatic (82%) and mucosal (86%)
involvement.114 Steroids could be tapered by 50% after a median
of 12 (range 4–23) procedures, and could be discontinued dur-
ing ECP in three patients. After a median follow-up of 52 (range
6–108) months, 10 of the 15 patients (67%) were alive. Toler-
ance of ECP was generally good, the main limiting factors being
vascular access and the psychological impact of repeated aphere-
sis procedures. Furthermore, children weighing less than 25 kg
were not any more susceptible to side-effects compared with
patients weighing more than 25 kg.
In summary, ECP is a safe and efficacious form of cGVHD
therapy, with steroid-sparing capacity. A venous access for ther-
apy is required and peripheral veins should be used preferen-
tially to avoid central line-associated infections. Further
prospective clinical studies are warranted to assess the efficacy of
ECP in homogeneous cohorts of cGVHD patients treated earlier
in the course of disease.
Existing clinical guidelines
In 2008, Scarisbrick and colleagues50 published a UK consensus
statement on the use of ECP for the treatment of cGVHD. In this
statement, it was decided that ECP should be considered for
patients with cGVHD who are refractory to, dependent on, or
intolerant of corticosteroids.
Recently, recommendations of a joint working group estab-
lished by the Haemato-oncology subgroup of the British Com-
mittee for Standards in Haematology (BCSH) and the British
Society for Blood and Marrow Transplantation (BSBMT) have
been published, based on review of the available literature.110 In
these guidelines, ECP was strongly recommended (grade 1b) as
second-line therapy for skin, oral and liver manifestations of
cGVHD, with a schedule of fortnightly paired treatments for a
minimum assessment period of 3 months. Grade 1 recommen-
dation means that there is confidence about the benefits of ECP,
and no other immunosuppressive therapeutic modality received
a stronger recommendation for second-line therapy of cGVHD.
Furthermore, ECP was recommended as a third-line treatment
option in cGVHD involving other organs (grade 2C). It was
observed that infections requiring systemic antibiotics may be
halved in patients receiving ECP.
The German/Austrian/Swiss consensus conference on second-
line treatment of cGVHD in daily clinical practice recommended
ECP with a strength of recommendation of C-I, meaning use in
second-line treatment is justified, based on grade II evidence.85
Of note, ECP was considered superior to other novel immuno-
suppressive agents, due to its excellent safety profile and steroid-
sparing effect. These recommendations were based on the fact
that numerous investigators had reported high response rates in
skin, liver and oral manifestations of steroid-refractory cGVHD
and improved survival rates both in children and in adults. Con-
sidering the use of ECP in the first-line treatment of cGVHD,
the German/Austrian/Swiss consensus conference stated that,
while ECP has been found to be associated with a steroid-spar-
ing capacity and favourable side effect profile, there are currently
insufficient data to support the use of ECP in first-line treatment
but that further studies are highly warranted.85
In 2007, Kanold and colleagues published clinical practice
guidelines on the use of ECP in children with cGVHD after allo-
geneic marrow transplantation, based on field experience and a
review of the literature.95 In these guidelines, ECP was recom-
mended in paediatric patients with cGVHD not responding to
steroids, defined as stable disease after 1 month of steroid treat-
ment, PR after 2 months of steroids, or progression of cGVHD
after 2 weeks of steroid treatment. Thus, ECP was recommended
as second-line therapy of cGVHD not responding to corticoster-
oids. Furthermore, ECP was recommended in paediatric patients
with severe cGVHD with steroid-intolerance, and in steroid-
refractory or steroid-dependent paediatric patients after more
than three lines of immunosuppressive therapies. In view of the
excellent safety profile of ECP, Kanold and colleagues considered
ECP as first-line therapy for paediatric patients with limited
cGVHD regardless of other therapies administered.
Recommendations
Patient selection Patients with moderate or severe cGVHD
according to National Institutes of Health (NIH)-defined crite-
ria121 should receive systemic therapy. Mild manifestations of
cGVHD that cannot be treated sufficiently by topical agents,
such as hepatic manifestations or fasciitis, may also be treated
with systemic corticosteroids for first-line therapy. Currently, no
uniformly accepted definition of steroid-refractory cGVHD is
available and generally accepted criteria include progression on
prednisone at 1 mg/kg/day for 2 weeks, stable disease on at least
0.5 mg/kg/day for 4–8 weeks and inability to taper steroids
below 0.5 mg/kg/day.85
For second-line therapy of steroid-refractory cGVHD, all
patients are eligible to receive ECP, except those with total leuco-
cyte counts below 1.0 G/L, intolerance to methoxsalen, heparin
or citrate products, and hemodynamic instability due to ongoing
life-threatening infections or severe bleeding events.
Treatment schedule No general recommendation can be made
on treatment schedule, due to missing evidence. Typically,
patients would receive one cycle of two ECP treatments every
1–2 weeks for weeks 0–12. After week 12, treatment intervals
could possibly be increased by 1 week every 3 months, depend-
ing on the type of lesions, extent of cGVHD and clinical
response. If cGVHD progresses, a change in treatment strategy
should be considered.84,85
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Response assessment Response should be assessed according
to the NIH guidelines.122
Acute graft-versus-host disease
aGVHD, like cGVHD, is a serious complication of allogeneic
HSCT, and a key cause of transplant-related morbidity and mor-
tality, mainly due to severe infections and organ toxicities.123
Furthermore, aGVHD is an important risk factor for the later
development of cGVHD. Currently, standard first-line therapy
consists of corticosteroids; however, only up to 50% of all
patients respond to therapy and thus a substantial proportion of
patients with aGVHD require salvage treatment.123–126 So far, no
immunosuppressive agents have been approved for the treat-
ment of steroid-refractory aGVHD. Despite many studies, prac-
tices vary considerably regarding the selection of agents for
treatment of steroid-refractory aGVHD. Recently, Martin and
colleagues published recommendations of the American Society
of Blood and Marrow Transplantation for the treatment of
aGVHD based on a comprehensive and critical review of
published reports.123 Across the 67 studies selected with well-
defined evaluation criteria, 19 different agents were investigated.
Besides horse antithymocyte globulin (ATG), ECP was the most
frequently studied therapeutic option. Approximately, 300
patients with steroid-refractory aGVHD given ECP have, so far,
been reported in numerous publications, with an increasing
number during recent years.89,93,95,97–99,113,114,116,119,127–135
Overall, CR and PR of cutaneous manifestations were observed
in a median of 75% (range 50–100%) of patients, CR and PR of
hepatic involvement were observed in a median of 47% (range
0–100%) of patients, and CR and PR of GI manifestations were
observed in a median of 58% (range 0–100%) of patients. ECP
was tolerated excellently and side-effects were mild, consisting
mainly of reversible drops in peripheral blood cell counts after
the first courses of ECP.
The results of studies with ECP in the second-line treatment
of aGVHD are summarized in Table 6.89,93,95,97,98,116,129–131,133
Following promising results in preliminary investigations,99 then
in a pilot study of 21 patients,119 Greinix and colleagues con-
ducted a phase II study of ECP in 59 adult patients with severe
aGVHD (both steroid-refractory and steroid-dependent).129 CR
rates for individual organs were 82% for skin involvement and
61% each for GI and liver involvement. Responses were highest
in patients with cutaneous symptoms only (87%), and lower for
those who had two organ systems involved (62% for skin and
liver involvement, 40% for skin and GI involvement), or those
who had all three organs affected (25%). Response rates were also
higher for patients with less severe grades of aGVHD at the start
of treatment (CR rate 86% for grade II, 55% for grade III and
30% for grade IV aGVHD). In contrast to the pilot study,119 an
intensified schedule of ECP was administered in the phase II
study, consisting of two to three treatments per week on a weekly
basis until maximum response. This strategy led to improve-
ments in CR rates in patients with grade IV aGVHD (60% vs.
12%) and GI involvement (73% vs. 25%) using the intensified
ECP schedule compared with the pilot study.128,129 Best response
to ECP was observed after a median of 1.3 (range 0.5–6) months
of treatment and no flare-ups were seen after tapering and dis-
continuation of corticosteroids. In ECP-responding patients,
corticosteroids could be discontinued after a median of 55 (range
17–284) days after the start of ECP. In univariate analysis, a lower
grade of aGVHD and fewer organs involved at the start of first-
line therapy with corticosteroids as well as at the start of ECP,
and a lower cumulative corticosteroid dose prior to ECP, signifi-
cantly increased the probability of CR of steroid-refractory aG-
VHD with ECP. However, in logistic regression analysis, only a
lower grade of aGVHD at the start of ECP and later onset of cor-
ticosteroid medication after HSCT were variables significantly
favouring the achievement of CR by ECP. The cumulative inci-
dence of transplant-related mortality at 4 years was 14% in
patients achieving a CR of steroid-refractory aGVHD, compared
with 73% in patients without CR, 3 months after the start of
ECP (P < 0.0001). Patients with a CR of steroid-refractory
Table 6 Summary of studies using extracorporeal photopheresis in the second-line treatment of acute graft-versus-host disease.
Patients (n) CR skin CR liver CR gut OS
Salvaneschi et al.89 9 67% (6/9) 33% (1/3) 60% (3/5) 67%
Dall’Amico et al.116 14 71% (10/14) 57% (4/7) 60% (6/10) 57%
Messina et al.93 33 76% (25/33) 60% (9/15) 75% (15/20) 69% at 5 years
Garban et al.130 12 67% (8/12) 0% (0/2) 40% (2/5) 42%
Greinix et al.129 59 82% (47/57) 61% (14/23) 60% (9/15) 47% at 5 years
Kanold et al.95 12 90% (9/10) 56% (5/9) 83% (5/6) 75% at 8.5 months
Calore et al.133 15 92% (12/13) - 100% (14/14) 85% at 5 years
Gonzales-Vicent et al.97 8 100% (8/8) 100% (2/2) 57% (4/7) 38%
Perfetti et al.131 23 65% (15/23) 27% (3/11) 40% (8/20) 48% at 37 months
Perotti et al.98 50 83% (39/47)† 67% (16/24)† 73% (8/11)† 64% at 1 year
†Combined CR and PR.
CR, complete response; OS, overall survival; PR, partial response.
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aGVHD with ECP had a significantly improved OS of 59%, com-
pared with 11% in patients without a CR (P < 0.0001). The
cumulative incidence of relapse at 4 years was 28%, which was
thus not increased when compared with HSCT patients not
receiving ECP. Treatment with ECP was well tolerated and no
increase in rates of infection was observed.
Perotti and colleagues recently reported excellent response
rates in 50 patients with steroid-refractory aGVHD and con-
firmed the corticosteroid-sparing effect of ECP.98 There was a
policy of early intervention in patients with aGVHD, so the
median time from onset of symptoms to start of ECP therapy
was 9 days. The OR rate was 68% (32% CR and 36% PR), with
similar response rates for the different organ systems (83% skin,
67% liver, 73% GI system). Furthermore, ECP-responders had a
significantly improved survival of 62%, compared with 6% in
aGVHD patients not responding to ECP (P < 0.001). Ability to
decrease the corticosteroid dose 30 days after the start of ECP
was associated with significantly decreased mortality, confirming
the importance of corticosteroid-sparing in aGVHD. Other
authors have also noted that the possibility of reducing or dis-
continuing immunosuppressive therapies, and particularly
ongoing corticosteroids, is a major advantage for ECP in
preventing long-term complications in children.93,95
Several studies of ECP have been conducted in paediatric
patients with aGVHD and have shown similar results to those
obtained in adults. A large, multicentre, retrospective study of
33 paediatric patients with steroid-refractory aGVHD showed,
overall, 54% CR and 21% PR.93 The CR for skin symptoms was
76%, for GI manifestations was 75%, and for liver involvement
was 60%. The five-year OS rate was significantly better for
responders (69%) than non-responders (12%; P = 0.001). As a
result of ECP, immunosuppressive therapy could be discontin-
ued in eight patients of 19 surviving patients (42%) and reduced
in seven (36%). The median Karnofsky performance score
improved significantly from 60% before ECP to 100% (range
80–100%) after completing ECP therapy.
Supporting data come from subsequent small studies using
the twice-weekly ECP treatment regimen.97,132 In 15 paediatric
patients with steroid-refractory aGVHD, the strongest predictor
of response to treatment was disease stage: there was a 100%
response rate for stage II, 75% for stage III and 0% for stage
IV,132 with stage of GVHD and response to ECP both being sig-
nificant predictors of transplant-related mortality. A comparison
of ECP and steroid therapy in paediatric patients also showed
somewhat better results for ECP.133 Following ECP treatment,
73% of the 15 patients showed a CR, and the remaining 27%
showed a PR; a CR was recorded in 92% of patients with skin
manifestations, 71% with GI manifestations, and 100% with
liver disease. In comparison, 56% of 16 patients receiving steroid
therapy showed a CR, and 31% a PR; two patients had persistent
cGVHD after 1 year. CR rates for different organs were 46% for
skin, 57% for GI system and 67% for liver. Transplant-related
mortality at day 100 of treatment was 6% for steroid therapy,
but no patients had died in the ECP group, and the 2-year OS
rates were numerically, but not significantly, higher for ECP
(85%) than for steroid therapy (57%).133
Several authors have pointed out that the use of ECP in chil-
dren presents specific challenges, such as low bodyweight, vascu-
lar access, extracorporeal volume, metabolic and haematological
problems, and psychological tolerance93,95,134 Nevertheless, Mes-
sina and colleagues were able to treat patients with a bodyweight
as low as 10 kg without significant side-effects.93 Kanold and col-
leagues reported the follow-up of paediatric patients with
GVHD, with a particular emphasis on the technical aspects of
ECP therapy.95 Their efficacy results were similar to those from
other studies [7/12 patients (58%) with aGVHD showed a CR
and 3/12 (25%) a PR]. They observed good treatment tolerability
in patients with low bodyweight, and emphasized the importance
of a dedicated paediatric environment and care team to manage
challenges such as vascular access and psychological tolerance
that might be particularly prominent in the paediatric setting.95
The challenge of treating low-bodyweight paediatric patients
(as low as 15 kg) was also addressed in a study of patients with
both aGVHD and cGVHD.134 In contrast to many groups that
have used an ‘offline’, two-stage technique for mononuclear
cell collection and irradiation,95,97,98 this group reported the
use of a sterile, closed-loop procedure, in which patients
received fluid boluses of normal saline or 5% albumin to boost
blood volume before, and if needed during, ECP procedures.
The process was well tolerated by patients, and therefore could
extend the use of continuous-flow ECP to these patients with
low body weight.
In addition to these studies of treatment of aGVHD, preli-
minary studies have investigated the use of ECP as part of the
myeloablative conditioning regimen, prior to HSCT, in an
attempt to reduce the incidence of aGVHD. Miller and col-
leagues showed a lower than expected incidence of severe aG-
VHD when ECP was used as part of a novel reduced-intensity
conditioning regimen, with no negative effects on engraftment
or disease relapse.136 However, in a phase II study of the addi-
tion of ECP to cyclosporine and methotrexate (all as aGVHD
prophylaxis) in a standard myeloablative regimen, the incidence
of aGVHD was similar to that found in other studies.137 Com-
parison of the ECP-treated group with historical controls did
appear to indicate a somewhat lower incidence of grades II–IV
aGVHD and a longer OS for patients when ECP was included in
conditioning.137 Therefore, this preventive use of ECP may have
some benefits, but data from more patients with a longer dura-
tion of follow-up are needed to assess this.
In conclusion, ECP is well tolerated, with an excellent safety
profile in children and adults and is highly efficacious in aG-
VHD. Early start of ECP in steroid-refractory patients, with an
intensified ECP schedule consisting of two to three treatments
per week and rapid tapering of corticosteroids during ECP, are
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important variables significantly impacting on the response to
ECP and patients’ survival. Further prospective studies are war-
ranted, including the use of ECP in upfront therapeutic or pro-
phylactic strategies.
Existing clinical guidelines
The American Society for Apheresis (ASFA) reviewed the data
available on ECP in aGVHD up to early 2013.138 They concluded
that OR rates for steroid-refractory aGVHD in paediatric and
adult patients range from 52% to 100%, with responses in skin,
GI tract and liver ranging from 66% to 100%, from 40% to 83%
and from 27% to 71%, respectively, and that CRs outnumber
PRs. The ASFA recommended that ECP should be used on two
consecutive days (one series) performed weekly until disease
response and then tapered to every other week before discontin-
uation.
The recent BCSH/BSBMT guidelines for the diagnosis and
management of aGVHD recommended ECP as a second-line
therapy for the treatment of steroid refractory aGVHD, based on
level 2C evidence.126 They commented on the good tolerability
of ECP, but concluded that the optimal treatment schedule and
duration of treatment have yet to be established. However, Das
Gupta and colleagues reported a regimen of weekly cycles for a
minimum of 8 weeks continued until maximal response or
CR.135 Of note, no other immunosuppressive agent was recom-
mended with a higher level of evidence by the BCSH/BSBMT.
In 2007, Kanold and colleagues published clinical practice
guidelines for physicians caring for children with aGVHD, based
on expert opinion, analysis of current practice and some pub-
lished results.95 In these guidelines, ECP was recommended in
paediatric patients with aGVHD not responding to corticoster-
oids, defined as absence of clinical and biological improvement
after 1 week of corticosteroid therapy (up to 2–5 mg/kg/day).
However, the authors commented that the tendency to start
ECP earlier in the event of severe aGVHD, led them to consider
ECP as early as 48 hours after the initiation of corticosteroid
therapy in cases of insufficient efficacy. Thus, ECP was recom-
mended as second-line therapy of aGVHD not responding to
corticosteroids. In addition, ECP was recommended in paediat-
ric patients with severe aGVHD with steroid-intolerance, and
steroid-refractory or steroid-dependent paediatric patients after
more than three lines of immunosuppressive therapies, as well as
for grade IV aGVHD, in association with first-line immunosup-
pressive therapy. In view of the excellent safety profile of ECP,
Kanold and colleagues considered ECP as first-line therapy for
paediatric patients with grade IV aGVHD (in association with
conventional immunosuppressive approaches) and as second-
line therapy in steroid-refractory aGVHD of grades II–III. Rec-
ommendations were provided on vascular access and ECP tech-
nique in children, and the recommended schedule was to start
with ECP at three times weekly until maximal response was
achieved, followed by individual progressive tapering of therapy.
Recently, Martin and colleagues published recommendations
of the American Society of Blood and Marrow Transplantation
(ASBMT) for the treatment of aGVHD based on a comprehen-
sive and critical review of published reports.123 Data on
6-month survival and CR and PR of aGVHD in 67 reports sum-
marizing results of secondary systemic treatment did not sup-
port the choice of any specific agent for second-line therapy.
The results also provided no evidence that any specific agent
should be avoided for secondary therapy of steroid-refractory
aGVHD. Among the five studies with outliers in 6-month sur-
vival, the clinical trial on ECP by Messina and colleagues was
cited with an outlier high survival. Since only children were
treated, with a median age of 9.6 years, Martin and colleagues
concluded that these outliers could reflect age differences
between patient cohorts, as the benchmark study using horse
ATG included a patient cohort with a median age of 27 years.139
The ASBMT described the limited toxicity of ECP, including
blood loss from the extracorporeal circuit, hypocalcaemia due
to anticoagulant, mild cytopenia and catheter-associated bacter-
aemia, but no increased risk for infections beyond standard
therapy, and they specifically mentioned no concerns for
increased viral reactivations during ECP treatment. A typical
ECP schedule of three times weekly during the first week, fol-
lowed by twice weekly on a weekly basis, was described. Accord-
ing to the ASBMT recommendations, choice of second-line
regimen should be guided by considerations of potential toxic-
ity, interactions with other agents, familiarity of the physician
with the agent, prior experience of the physician with the agent,
convenience and costs.
Due to the excellent safety profile of ECP and the lack of
interactions with other agents, ECP compares favourably with
other immunosuppressive strategies, supporting its increasingly
frequent use as second-line therapy of steroid-refractory
aGVHD.
Recommendations
Patient selection Patients with aGVHD not responding to
first-line therapy with corticosteroids at 2 mg/kg/day, defined as
progression of aGVHD after ≥3 days of corticosteroid treatment
or lack of response after ≥7 days of corticosteroids, should
receive adjunct ECP as second-line therapy.
Treatment schedule Patients should be treated on a weekly
basis, with two to three treatments per week. There is currently
no evidence that maintenance ECP is beneficial. Thus, as soon as
patients achieve a CR, ECP can be discontinued.
Response assessment Activity of aGVHD should be assessed
every 7 days with staging according to published criteria.140,141
Assessments should relate to organ involvement. Quality of life
data are important in this group with multiple morbidities.
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Scleroderma
Scleroderma [systemic sclerosis (SSc)] is a multisystemic con-
nective tissue disease characterized by humoral and cellular
immune abnormalities and fibroblast activation. These changes
are associated with excessive deposition of collagen, and obliter-
ative vasculopathy primarily within the skin and frequently
within visceral organs such as the kidneys, heart, lungs and
digestive tract.142,143
The prognosis of SSc has been shown to vary depending on
both the extent of skin thickening and its rate of progression.
Cases restricted to the hands have a 10-year survival above 70%,
whereas cases with proximal involvement including the trunk
have a 10-year survival rate of only approximately 20%.144
Although the aetiology and pathogenesis of SSc are at present
unknown, evidence suggests that certain environmental agents
(organic solvents, specific tryptophan-containing products,
adulterated oils), genetic backgrounds (specific human leucocyte
antigen alleles such as DR-5) and/or viruses [retroviruses, cyto-
megalovirus (CMV)] may be associated with the development of
disease.
Interestingly, it has been shown that fetal CD3+ T cells from
prior pregnancies could be detected in the blood and lesional
skin of a significant proportion (>50%) of females with SSc,145
suggesting that, in certain cases, T-cell microchimerism may be
directly involved in the pathogenesis of SSc by initiating a graft-
versus-host-like response. Furthermore, clonal T-cell popula-
tions have been identified in the blood and skin of patients with
SSc.146–148
Therapeutic management of SSc is challenging. Both the low
prevalence (240 cases per million population) and the variable
prognosis of SSc make the evaluation of therapeutic responses
difficult and explain why many of the treatments currently used
have not been formally evaluated within randomized, controlled
trials. Skin thickening can be treated in various manners (meth-
otrexate, cyclophosphamide, ECP, allogeneic bone marrow
transplantation), but the US Food and Drug Administration has
to date not approved any therapies for SSc. No placebo-con-
trolled clinical trials exist showing clear superiority of one
therapy.
ECP has been evaluated in SSc in two randomized clinical tri-
als, one crossover trial, and two open trials. In the first multicen-
tre trial, 79 patients with SSc of recent onset (mean symptom
duration 1.83 years) and progressive skin involvement entered a
randomized, parallel-group, single-blinded clinical trial compar-
ing ECP treatments given on two consecutive days monthly with
treatment using D-penicillamine at a maximum dose of 750 mg/
day.149 At both the six- and ten-month evaluation points, the
mean skin severity score, mean percentage skin involvement and
mean oral aperture measurements were significantly improved
from baseline among those who received ECP. By comparison,
among the patients treated with D-penicillamine, none of the
parameters of cutaneous disease had improved significantly after
6 months of therapy, although for those individuals in whom
treatment was continued the mean skin severity score and mean
percentage skin involvement had improved by 10 months.
In a randomized, double-blind, placebo-controlled, multicen-
tre clinical trial reported by Knobler and colleagues in 2006, 64
patients with SSc were randomized to receive either active or
sham ECP on two consecutive days monthly for 12 months, and
severity of skin and joint involvement were assessed.150 A statis-
tically significant improvement in skin scores compared with
baseline was observed at 6 (P = 0.0024) and 12 months
(P = 0.008) among patients who had active ECP, but not those
on sham ECP. Comparison of skin scores between the two study
arms did not achieve statistical significance because of the small
sample size. Joint involvement was also significantly improved
after 6 (P = 0.002) and 12 months (P = 0.001) of active ECP
when compared with baseline. However, the study lacked suffi-
cient statistical power to reveal a significant difference in skin
and joint manifestations between the active and sham ECP arms.
In a crossover trial reported by Enomoto in 1999, 19 patients
with progressive SSc of less than 5 years’ duration were random-
ized into two groups: group A received ECP according to the
standard protocol for 1 year, and group B received no treat-
ment.151 The main outcome parameter was the skin score after
1 year of treatment compared with that of the control group.
The results obtained could not show a statistically significant
effect of ECP in this relatively small patient population, although
the average skin score improved by 5% [standard error (SE)
21%] in group A (ECP) and deteriorated by 5% (SE 14%) in
group B (sham; not significant; P = 0.71). Approximately 1 year
after crossover, the skin scores reversed to what would have been
expected, with an average increase of 5% per year.
A single-centre, open trial of ECP in 11 women with progres-
sive SSc of recent onset, who were treated for a period of 16–
57 months, revealed an overall improvement and/or stabiliza-
tion of skin changes and physical performance in 5 of the 11
patients (45%).152 Extracutaneous manifestations deteriorated
in 10 of the 11 patients (91%; P < 0.05) and quality of life dete-
riorated in 9 of the 11 patients (82%; P < 0.05). This small,
open, single-centre trial suggested that ECP provides minor
improvement of skin changes in a subset of SSc patients without
improving extracutaneous manifestations or quality of life.
Finally, a recent study in 16 patients with diffuse cutaneous
SSc, who each received a total of 12 ECP treatments, reported a
reduction in dermal thickness and an improvement in joint
mobility, while internal organ involvement remained stable.153
This study also investigated the immunomodulatory effects of
ECP in the patients, which demonstrated an increase in Tr1 and
Treg cells as early as post-second cycle of ECP treatment and a
concomitant decrease in Th17 cells. In addition, there was a shift
from pro- to anti-inflammatory and anti-fibrotic cytokines, with
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an increase in IL-10, IL-1Ra and HGF and a decrease in TGF-
beta and CCL2. Furthermore, there was a direct positive correla-
tion between the reduction of IL-17 levels and skin thickness.
Taken together, ECP performed on two consecutive days
every month is well tolerated in SSc and may have beneficial
therapeutic effects on skin involvement that may not be detect-
able in small trials. Two controlled trials report beneficial effects
of ECP on skin, whereas one of three smaller studies suggests
there is no significant benefit. It may be that there is an effect in
specific subtypes but this remains to be determined by appropri-
ate clinical studies. For example, for localised scleroderma
refractory to PUVA, there are reports that use of ECP can be
associated with clinical responses.154
Existing clinical guidelines
None.
Recommendations
Patient selection On the basis of its safety profile, ECP should
be used in SSc as second-line or adjuvant therapy in mono- or
combination therapy, and it is recommended that it should be
applied in early progressive disease. In case of aggressive
advancement of the disease, ECP should be considered as an
approach to treat skin, but not organ, involvement.
Treatment schedule In the randomized, double-blind, pla-
cebo-controlled trial of ECP in SSc published by Knobler and
colleagues,150 ECP treatment was performed on two consecutive
days (one treatment cycle) every 4 weeks for 12 months. There
is evidence to support an increase in the frequency of treatments,
which may have a positive effect, and the group of experts con-
sidered that there will be a benefit with two treatments per
month.
Maintenance should consist of one treatment cycle per month
for skin symptoms of SSc only. To stop ECP, treatment intervals
should be increased by 1–2 weeks every 3 months. Based on the
clinical course over a reasonable significant period of time, indi-
vidual centres must make a clinical judgement on whether a
patient is responding to ECP therapy or not. If no response is
noted, then the ECP treatment intervals should be increased, or
a pause introduced to follow the course of the disease without
ECP.
Response assessment Clinically and photographically, using
validated scoring systems.
Solid organ transplantation
Lung transplantation
Based on recent International Society of Heart and Lung
Transplantation (ISHLT) registry data, more than 2700 lung
transplantation procedures were performed in 2010.155 Despite a
shift towards more potent immunosuppressive regimens, the
development of acute and chronic allograft rejection continues
to impact negatively the long-term survival of lung transplant
recipients. It is estimated that acute rejection of the transplanted
lung occurs in more than 30–50% of recipients and is one of the
major risk factors for chronic rejection, which remains the most
common cause of death after the first year.
Bronchiolitis obliterans syndrome (BOS) represents chronic
allograft rejection and occurs in more than 60% of lung trans-
plant survivors 5–10 years after the transplant.156 Bronchiolitis
obliterans is a pathological process that affects small airways. It
can be difficult to diagnose by transbronchial biopsy and thus
diagnosis is made on the basis of graft deterioration due to per-
sistent airflow obstruction rather than by histological confirma-
tion. BOS is characterized clinically by progressive dyspnoea and
airflow limitation with declining forced expiratory volume in
1 second (FEV1) that cannot be explained by other causes such
as acute rejection or infection. According to the ISHLT staging
system for BOS, stage 0 signifies no significant abnormality and
an FEV1 of >90% of the best postoperative value, whereas stage
3 signifies severe BOS with an FEV1 of ≤50%.157 Potential BOS
(0-p), defined as an FEV1 of 81–90%, was added to detect early
changes in graft function that might predict the onset of stage 1.
BOS is a major factor limiting long-term survival after lung
transplantation, which is approximately 50% at 5 years. The
most precipitous decline in airflow typically occurs in the first
6 months following a diagnosis of BOS, although the time of
onset of BOS and rate of decline of FEV1 are highly variable.
At the time of transplantation, many transplant centres now
employ an induction regimen that includes infusion of an
antibody that targets activated host lymphocytes. Such agents
include polyclonal anti-T-cell preparations such as ATG, or
monoclonal agents aimed at lymphocyte surface molecules such
as IL-2 receptor/CD25 (daclizumab, basiliximab) or, less com-
monly, CD52 (alemtuzumab).158 Maintenance immunosuppres-
sive therapy after lung transplantation typically comprises of
a three-drug regimen consisting of a calcineurin inhibitor
(cyclosporine or tacrolimus), an antimetabolite (azathioprine or
mycophenolate mofetil) and steroids. Short courses of intrave-
nously pulsed corticosteroids, followed by a temporary increase
in maintenance doses for a few weeks, are the preferred treat-
ment for uncomplicated acute rejection. The initial treatment of
BOS usually consists of repeated pulses of high-dose methyl-
prednisolone. Additional therapeutic options are augmentation
of existing regimens, and/or switching within classes of drugs.
Successful treatment of BOS is usually defined as ‘stabilization’
or ‘slowing’ of FEV1 decline rather than true improvement or
normalization of airflow. For patients with unresponsive BOS,
salvage immunosuppressive regimens have included ATG,
OKT3, alemtuzumab, as well as addition of other agents or
interventions including methotrexate, cyclophosphamide,
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inhaled cyclosporine, sirolimus, total lymphoid irradiation and
surgical treatment of gastro-oesophageal reflux disease if present.
More recently, the macrolide antibiotic azithromycin has shown
efficacy in improving FEV1 in lung transplant recipients suffer-
ing from BOS.159
ECP has been utilized as a salvage therapy for the treatment of
lung transplant rejection when conventional therapies have not
produced an adequate response.160 Importantly, ECP is not
associated with an increased risk of infection, which is common
with immunosuppressant drugs.138 The first introduction of
ECP in human lung transplantation was performed in 1995 for
an acute rejection episode occurring in severely infected
patients,161 who improved clinically after 3 weeks and histologi-
cally after 4 weeks. During the same year, ECP was used in three
patients with chronic lung rejection that was refractory to ste-
roid treatment, allowing stabilization of the degradation of their
pulmonary function.162 ECP was performed at monthly intervals
without significant complication. ECP was then implemented
for refractory BOS, with stabilization of pulmonary function and
improvement in survival after monthly treatments performed on
two consecutive days.163,164 Villanueva and colleagues reported
their experiences with ECP in 14 lung transplant patients all
diagnosed with BOS, who received 3–13 (median 6) ECP treat-
ments.164 In the three patients with a concurrent acute rejection,
ECP led to the resolution of this. Of the eight patients with BOS
grade 1, four improved or remained stable, while two progressed
to grade 2 and the last died of lung cancer. Those with grade 2–3
BOS did not improve on ECP (five died and one was retrans-
planted).164
O’Hagan and colleagues described five patients with severe
BOS refractory to augmented immunosuppression such as
methotrexate, ATG and OKT3. A temporary stabilization of the
airflow obstruction was observed in three patients during ECP.
However, a high rate of complications was reported as a conse-
quence of the total augmented immunosuppression: one patient
developed a lymphoproliferative disease and there were three
opportunistic infections that resulted in two deaths.163 A similar
experience was reported by Salerno and colleagues in eight
patients, including seven with BOS: five patients improved on
ECP, with a histological reversal of rejection in two patients.
After a follow-up of 36 months, four patients remained in a sta-
ble condition without any complication related to ECP.165
Benden and colleagues reviewed a single-centre experience
with ECP for BOS and recurrent acute rejection after lung trans-
plantation, with 12 patients in each group treated.166 In trans-
plant recipients with BOS, the decline in FEV1 was 112 mL/
month before the start of ECP and 12 mL/month after 12 ECP
cycles (P = 0.011), with a mean (95% confidence interval)
change in rate of decline of 100 (28–171 mL/month). ECP thus
reduced the rate of decline in lung function in recipients with
BOS and was well tolerated. Furthermore, recipients with recur-
rent acute rejection experienced clinical stabilization.
In another single-centre study, Morrell and colleagues analy-
sed the efficacy and safety of ECP for progressive chronic rejec-
tion.167 A total of 60 lung allograft recipients were treated with
ECP for BOS and showed a significant reduction in the rate of
decline in lung function.
Jaksch and colleagues performed a prospective interventional
study that included 51 patients with BOS who were treated with
ECP between 2001 and 2011.168 A total of 31 (61%) responded
to the therapy and showed sustained stabilization of lung func-
tion (FEV1 range –5% to +5% compared with baseline at the
start of ECP) over 6 months. Responders to ECP showed signifi-
cantly greater survival and less need for re-transplantation than
non-responders (P = 0.0001). Factors associated with an inferior
treatment response were cystic fibrosis as an underlying lung dis-
ease and a longer time between transplantation and development
of BOS. Compared with non-ECP-treated patients, those
responding to ECP showed an improved graft survival
(P = 0.05).
In a very recent study, Greer et al. performed a single centre,
retrospective analysis of all patients treated with ECP for chronic
lung allograft dysfunction (CLAD) during a contemporary four
year period, with the primary goals being to identify factors pre-
dicting treatment response and the prognostic implications.169
Of a total of 65 patients treated with ECP, 64 had deteriorated
despite treatment with azithromycin. Median follow-up after
starting ECP was 503 days. At the start of ECP, all patients were
categorized into the following clinical phenotypes: restrictive
allograft syndrome (RAS), neutrophilic CLAD (nCLAD) and
rapid decliners. At follow-up, 12.3% had a ≥ 10% improvement
in FEV1, 41.5% stabilized, and 46.2% had a ≥ 10% decline in
FEV1. Patients meeting the criteria of rapid decliner (32.3%,
P = 0.005), RAS (33.8%, P = 0.002) and those not exhibiting
neutrophilia in bronchoalveolar lavage (67.7%, P = 0.01) exhib-
ited poorer outcomes. ECP was an effective treatment in approx-
imately 54% of patients with CLAD who had failed
azithromycin, and those who responded were found to have a
statistically improved progression-free survival (median 401 vs.
133 days).
A possible marker for ECP response could be the level of
Treg-cells, which increase after photopheresis. It is interesting to
note that after ECP for lung transplantation the levels of Treg-
cells did not correlate with the number of ECP treatments, but
rather with lung function itself.170
In summary, there have been a few retrospective papers and
one prospective study on the use of ECP in lung transplant
recipients. In most reports, ECP was used in patients with BOS,
but there are a small number of cases with acute and/or recur-
rent/ongoing rejection episodes. Furthermore, in several case
series reports with ECP, lung transplant recipients who were
unresponsive to standard immunosuppressive therapy and who
had deterioration of graft function due to refractory BOS or
persistent acute rejection experienced stabilization of lung
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function and/or symptoms.162,163,166,170,171 There are no studies
to date addressing the prophylactic effect of ECP for lung trans-
plantation.
Cardiac transplantation
Based on recent ISHLT registry data, more than 3700 cardiac
transplantation procedures were performed in 2010. It is esti-
mated that acute rejection of the transplanted heart occurs in
more than 25–40% of recipients within the first year and
approximately 5% will result in severe hemodynamic compro-
mise.155,172–175
Although major improvements have been made in the pre-
vention and treatment of acute transplant rejection, accelerated
cardiac allograft vasculopathy (CAV) still limits the long-term
success of heart transplantation.176 After the first year, CAV is
the second most common cause of death, after malignancy. Its
pathogenesis, although not fully understood, is characterized by
a fibroproliferative process affecting all cardiac arteries and
resulting in concentric narrowing, obliteration and, ultimately,
allograft failure.176 CAV is detectable by angiography in 5% of
survivors within the first year and in over 27% within the first
5 years.177–181 Patient survival is diminished significantly after
the detection of CAV, and CAV and graft failure (most likely
undetected CAV) are, in addition to malignancy, the most
important causes of death in patients who survive the first year
after transplantation.176
The first reports of ECP therapy for cardiac transplant rejec-
tion surfaced in 1992. These early reports showed rapid biopsy-
proven reversal of acute cardiac rejection after 2–4 ECP treat-
ments. By 1998, the first multicentre, randomized clinical trial
was published.182 In this study, 60 cardiac transplant recipients
were randomized post-transplant to receive standard triple
immunosuppressive therapy vs. standard triple immunosuppres-
sive therapy plus ECP started within 30 hours of the transplant
surgery. After 6 months of follow-up it was clear that the addi-
tion of ECP (10 treatments in month 1, four treatments in
months 2 and 3, and two treatments in months 4, 5 and 6)
resulted in significantly fewer cardiac rejection episodes
(P = 0.03). There were no significant differences in the time to a
first episode of rejection, the incidence of rejection associated
with hemodynamic compromise or survival at 6 and 12 months.
Interestingly, detection of cytomegalovirus DNA in the plasma
by PCR was reduced significantly in the ECP cohort
(P = 0.036).182
Shortly thereafter, a pilot, prospective, randomized study was
published to determine whether the addition of prophylactic
ECP to a triple immunosuppressive regimen in cardiac trans-
plant recipients resulted in decreased levels of panel reactive
antibodies (PRA) and CAV.183 Twenty-three cardiac transplant
recipients were randomized to receive standard triple immuno-
suppressive therapy vs. standard triple immunosuppressive ther-
apy plus ECP started within the first month after transplantation
(2 treatments per month 9 12, 2 treatments every 6–8 weeks
during months 12–24). Although there were no differences
between the two groups in the incidences of infection or acute
rejection, the ECP group had a significant reduction in PRA lev-
els and intimal proliferation by intravascular ultrasound (a sur-
rogate for CAV) at 12 and 24 months.183
In 2006, Kirklin and colleagues published a retrospective
review of 13 years’ experience of managing cardiac transplant
rejection.184 The group compared the fate of 36 patients who
received at least 3 months of ECP for hemodynamically compro-
mised (HC) or recalcitrant rejection with that of 307 patients who
did not receive ECP. Survival and risk factors were examined by
analysis using multivariate hazard function modulated renewal
function. After 3 months of ECP, rejection risk was decreased
(P = 0.04) and the hazard for subsequent HC rejection or rejec-
tion death was significantly reduced towards the risk-adjusted
level of lower risk non-ECP patients (P = 0.006). This study was
the first to suggest that ECP reduces the risk of subsequent HC
rejection and death in patients with high rejection risk.184
Despite the evidence from some studies showing that ECP
might be a valuable adjunct to standard immunosuppression in
cardiac transplantation, there are no clear guidelines or recom-
mendations on the use of ECP in this indication. Furthermore,
there are still several unanswered questions such as the identifi-
cation of responders, the best timing for ECP (when to start,
when to stop), how to monitor response and whether ECP can
replace the use of drugs. Although studies report a benefit, the
protocols used varied considerably and there are scarce data to
provide guidance on which patients should be treated with ECP
and when. In addition, adjuvant immunosuppressive protocols
used in the studies vary significantly and may have had a consid-
erable impact on the outcome. It will therefore be essential to
conduct a prospective, randomized, multi-centre trial to answer
the question of whether there is a role for ECP in cardiac trans-
plantation.185
Other organ transplantation
ECP has, over the years, been used to control rejection following
face,186 liver 187–190 and kidney 191–198 transplantation. In 2007,
Urbani et al. published a prospective study in 36 liver transplant
patients with ECP to delay calcineurin inhibitor use in patients
felt to be at high risk of renal and neurological complication
post-transplantation.199 The ECP treatment schedule was at days
2 and 6 post-transplant, then weekly in the first month, followed
by weekly or monthly treatments depending on liver function
test results. No significant difference was seen between the two
groups with regard to rates of biopsy-proven acute rejection,
time to rejection, nephrotoxicity, neurotoxicity or mean dura-
tion of hospitalization. There was a statistically significant higher
survival rate in the ECP cohort.
Recently, Kusztal et al. evaluated the biological responses of
ECP combined with conventional immunosuppressive therapy
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as prophylactic treatment in a prospective randomized study of
10 kidney transplant patients compared with a control group of
10 patients only receiving a calcineurin inhibitor, mycopheno-
late, and steroids.200 A total of 12–16 ECP treatments were per-
formed over 2.5 months. The ECP group showed a positive
trend to a higher estimated glomerular filtration rate (eGFR) at
3 months (53  11 vs. 47.1  9; P = 0.17) and was statistically
significant at 6 months (67.5  10 vs. 53.6  3; P = 0.03, Wil-
coxon test). An increased percentage of Treg (CD3+ CD4+
CD25+) among the total CD3 cell count (4.9  1% to
9.4  15%) as well as inducible Treg (CD3+ CD8+ CD28) was
observed among CD3 cells (3.3  3% to 11.8  8%, P = 0.025)
within 3 months of ECP treatment. A significant difference in
the percentage of Treg was noted at month 3 between the ECP
and the control groups (9.4  15% vs. 3  1%; P = 0.01).
Existing clinical guidelines
The British Photodermatology Group and the UK Skin Lym-
phoma Group 74 noted that there was good evidence to support
the use of ECP for the treatment of acute and recurrent acute
cardiac rejection, prophylaxis of cardiac rejection and chronic
cardiac rejection. At that time, there was poor evidence to
support the use of ECP for the management of renal or lung
allograft rejection.
More recently, in 2013, ASFA published guidelines on the use
of therapeutic apheresis in clinical practice.138 The guidelines
suggested that ECP may be appropriate for the treatment of lung
transplant rejection in selected individuals with persistent acute
rejection and early BOS. For cardiac allograft rejection, ECP
prophylaxis was rated category I, evidence 1A (strong
recommendation, high-quality evidence) and ECP treatment of
cardiac allograft rejection was rated category II, evidence 1B
(strong recommendation, moderate-quality evidence).
Recommendations
Patient selection
• After lung transplantation, the main indication for ECP is
currently in patients with chronic allograft dysfunction
(BOS). As mentioned above, patients with early onset of
BOS (within the first 3-year post-transplant) seem to
respond better to the treatment. ECP should be started as
soon as possible after a diagnosis of BOS is established. In
other indications (as a form of induction therapy, as a res-
cue therapy in cases of recurrent or ongoing acute cellular
rejection), ECP has been used with promising results but
there are, as yet, no recommendations published or avail-
able.
• For patients undergoing cardiac transplantation there are
some studies that support ECP as a valuable addition to
immunosuppressive regimens, but the protocols vary con-
siderably in both the ECP and immunosuppressive
regimens used. It remains unclear whether routine use of
ECP in cardiac transplantation would be beneficial and ECP
cannot be fully recommended until a prospective, random-
ized, multi-centre trial is conducted to provide a final
answer. Nevertheless, ECP appears to be a promising strat-
egy for patients with either treatment-resistant or recurrent
rejection episodes.
Treatment schedule One treatment cycle consists of ECP on
two consecutive days. A common regimen includes one cycle
every 2 weeks for the first 2 months, followed by once monthly
for 2 months (total of six). The optimal duration remains unan-
swered, and the number of treatment cycles ranges from 6 to 24.
If clinical stabilization occurs with ECP, long-term continuation
might be warranted to maintain the clinical response. In a
recent, 10-year, single-centre experience, 12 cycles was the initial
‘dose’ and long-term continuation was recommended for
responders.
Response assessment Efficacy of ECP is routinely monitored
using the pulmonary function test, with the FEV1 value a surro-
gate-marker for grade of BOS and response to therapy. Success-
ful treatment of BOS is usually defined as ‘stabilization’ or
‘slowing’ of FEV1 decline instead of true improvement or nor-
malization of airflow.
Crohn’s disease
Crohn’s disease is a chronic progressive inflammatory disorder
of the GI tract – it can affect any segment of the tract, but mostly
involves the terminal ileum and colon. Stricturing and penetrating
complications arise as sequelae of inflammation, necessitating
intestinal surgery in the majority of patients.201 Evidence sug-
gests that Crohn’s disease derives from perturbations at the
interface between the intestinal microbiota and the innate
immune system, based on genetic predisposition, which result in
mucosal hyperimmunity and inflammation.40 Thus, current
treatment strategies almost exclusively harness immunosuppres-
sive mechanisms of action, and include steroids, thiopurines,
methotrexate and anti-TNF-a agents. Such treatment strategies
are associated with an increased risk of infection, however, and
recently advocated strategies combining thiopurines and anti-
TNF-a agents may increase this risk further.202
Data on the use of ECP in Crohn’s disease remain scarce and
uncontrolled. A small single-centre study evaluated the use of
ECP in patients with prospectively evaluated steroid-dependent
Crohn’s disease.39 ECP was administered as two treatments
every 2 weeks, for a total of 24 weeks. In four out of nine
patients (44%), steroid therapy could be completely withdrawn
during ECP, without relapse of symptoms; in another four
patients, the dose of steroid could be reduced by at least 50%;
only one patient, with long disease duration and a high baseline
steroid dose, experienced therapeutic failure. In a subsequent
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multi-centre study (CD1 study), patients with steroid-dependent
Crohn’s disease received two treatments every other week, for a
24-week steroid-tapering period, and underwent a forced ste-
roid-tapering protocol.203 Steroid-free remission was achieved in
seven out of 31 patients (23%). In general, steroid-free remission
is an endpoint which is difficult to achieve in patients with ste-
roid-dependent Crohn’s disease that is refractory to, or intoler-
ant of, other therapies, including immunosuppressants or anti-
TNF-a agents. From the literature, a steroid-free remission rate
of a maximum of 25% is expected to be achieved by a switch to
a second-line anti-TNF-a agent, whereas the placebo steroid-free
remission rate is close to 0%.204
The CD2 study followed a different approach. Patients with
moderate-to-severe active Crohn’s disease refractory to immu-
nomodulators and/or anti-TNF-a agents received ECP twice
weekly for 4 weeks, tapering to twice every other week for
another 6 weeks.205 Among the 28 patients included, there was a
marked reduction in the Crohn’s Disease Activity Index score
during the 12-week treatment period, with 14 patients (50%)
being classified as responders, and seven patients (25%) achiev-
ing remission.
Existing data show some promise for the use of ECP in Cro-
hn’s disease. To date, two indications have been investigated in
open-label trials, namely steroid-dependent Crohn’s disease and
moderate-to-severe active Crohn’s disease. Most patients
included in these trials had shown no benefit following previous
exposure to the available standard care, including immunosup-
pressants and anti-TNF-a agents, and data are lacking on a
patient population less progressed in disease and therefore possi-
bly more sensitive to a tolerogenic response. Thus, a clear
demarcation of patients who could gain most from ECP is cur-
rently impossible. We are still waiting for proof of the efficacy of
ECP in Crohn’s disease outside of clinical trials, and it should
therefore be used primarily for patients with Crohn’s disease not
responding to, or intolerant of, standard care.
Existing clinical guidelines
None.
Recommendations
Based on published literature, ECP is generally well tolerated in
patients with Crohn’s disease and may help to control disease
progression in selected patients. However, at the present time,
no treatment recommendations can be made.
Atopic dermatitis
Atopic dermatitis (AD; atopic eczema) is a common, inflamma-
tory, chronically relapsing skin disease characterized by itchy
eczematous skin lesions which can affect the entire body surface
in severe cases.206–208 Histologically, the lesions of AD show
epidermal changes, including spongiosis and epidermal hyper-
plasia with slight hyperkeratosis and some parakeratosis
(depending on the disease stage), and dermal infiltrates com-
posed of T lymphocytes, monocytes and eosinophils. The exact
pathogenesis of AD remains unclear. A multifactorial trait
involving numerous gene loci on different chromosomes has
been proposed and the highest correlations have been shown
with mutations in the filaggrin gene associated with a disturbed
epidermal barrier function.206 A functional failure of Treg-
cells209,210 and an abnormal Th2/Th17-driven immune response
to exogenous and/or endogenous antigens seem to be the main
driving force in the genetically predisposed patients, leading to
the skin changes in AD.211,212 Clinical studies have demon-
strated a correlation between disease severity and levels of
immunoglobulin (Ig)E, and surrogate markers such as eosino-
phil cationic protein, soluble IL-2 receptor (sIL-2R) and soluble
E-selectin.213,214
In adults, AD typically has a chronic relapsing course associ-
ated with significant physical and psychological disability. The
disease usually responds adequately to emollients, topical corti-
costeroids, calcineurin emollients, or phototherapy such as
UVA-1, 311 nm UVB or PUVA.206–208,215,216 In some patients,
however, standard therapy remains unsatisfactory. These
patients often require immunosuppression with systemic corti-
costeroids, azathioprine, methotrexate or cyclosporine to pre-
vent severe disability. More recently, third-line approaches
leading to diminished T-cell activation, including alefacept,
efalizumab, rituximab or intravenous IgG, have been found to
be effective in severe cases of AD.206 Treatment with the anti-
IgE antibody omalizumab or the anti-IL-5 mepolizumab has
also revealed promising results in moderate-to-severe cases of
AD. These systemic therapies, however, are associated with a
significant risk of adverse effects. In contrast, ECP has been
used as a very safe treatment modality in severe cases of
AD.217–226
Prinz and colleagues first described, in 1994, the successful
administration of ECP in the treatment of three severe cases of
AD.217 Thereafter, several open clinical trials218–227 with mostly
small numbers of patients have corroborated that ECP may be
effective in severe cases of AD that are resistant to standard treat-
ment. In most studies, ECP cycles were administered in biweekly
intervals for at least 12 weeks and continued thereafter depend-
ing on the individual patient response. In the largest study so far
reported, Radenhausen and colleagues222 administered ECP to
35 patients with severe generalized AD over a period of 6–10
cycles. ECP led to a significant decrease (P < 0.05) in SCORing
Atopic Dermatitis (SCORAD) score from 74.4 before to 36.8
after ECP therapy (after a mean of 10 cycles). Approximately,
70% of patients had a favourable response to ECP, requiring at
least six cycles.
The results of all studies of ECP in AD are summarized in
Table 7.217–227 In an attempt to categorize the patient response
in order to be able to compare the different studies the rates
were as follows: CR 13%, PR 39%, minor response 22%, no
© 2013 The Authors. Journal of the European Academy of Dermatology and Venereology
published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.JEADV 2014, 28 (Suppl. 1), 1–37
22 Knobler et al.
response 25% in the pooled data of 67 patients with AD from
those studies. The reported percentages of SCORAD reduction
ranged from 16% to 99%. ECP seems to be particularly effective
in patients with first-line-therapy-refractory erythrodermic AD
when an intensified treatment regimen is administered and
maintained with treatment cycles given over longer periods of
time226 and/or in combination with other systemic treat-
ments.227 In the most recent trial of ECP in AD,220 a prospective
study set-up revealed that a defined 20-week ECP protocol led to
a SCORAD reduction of greater than 25% in only three of 10
patients. In all patients together, the authors observed on aver-
age a small but significant reduction in SCORAD from 64.8 at
baseline to 54.5 at week 20 (i.e. a reduction of 15.9%). However,
improvement in quality of life measured by different scores,
including SKINDEX, SF-36 or FACT, did not reach statistical
significance.220 It is intriguing to note that ECP has also been
shown to be effective in erythroderma of other origin, such as
red man syndrome,228,229 erythrodermic pityriasis rubra pilar-
is230 or photoaccentuated erythroderma associated with CD4+
T-lymphocytopenia.231
ECP has also been found to improve laboratory correlates of
active AD including elevated levels of IgE, eosinophilic cationic
protein, sIL-2R and/or soluble E-selectin.220–223 Radenhausen
and colleagues reported no significant correlation between a
decrease in these levels and values of blood eosinophils.222 In
comparison with ECP responders, most non-responders were
characterized by very high levels of total IgE before and during
therapy.222 No serious side-effects have been reported in AD
patients treated with ECP.220
In summary, several open clinical trials with small numbers of
patients have suggested that ECP is safe and may be effective in
severe cases of AD (including erythrodermic variants) that exhi-
bit resistance to standard treatment. Based on the existing data
and given the relative safety of ECP, it would be worthwhile
investigating its use in the treatment schedule of earlier phases
of AD.
Existing clinical guidelines
According to existing EDF guidelines it appears that ECP has an
effect in patients with AD.232 The level of evidence is not high
but, given the safety profile of ECP, further clinical studies
should be encouraged.
Recommendations
Patient selection According to the inclusion criteria of a pro-
spective, multi-centre, investigator-initiated study,220 ECP may
be considered in a patient with AD who fulfils the following cri-
teria: a diagnosis of severe atopic dermatitis: (i) of at least
12 months’ duration; (ii) SCORAD >45; (iii) resistance in the
last 12 months to all first-line therapies used to treat AD, includ-
ing topical steroids, topical calcineurin inhibitors, and one form
of phototherapy (UVA, UVB or PUVA) or resistance to either
systemic steroids or cyclosporine as second-line therapy.
Treatment schedule The initial ECP treatment for AD should
be one cycle (i.e. two consecutive treatment days) every 2 weeks
for 12 weeks, a schedule that has been applied in most previous
studies on the use of ECP in AD. Thereafter, ECP cycles may be
given in intervals depending on the individual response of a
patient, for example, every 4 weeks for another 3 months; at
maximal response, treatment should be tapered to one treatment
cycle every 6–12 weeks before stopping. Relapse can be treated
by returning to the interval frequency of the previously effective
treatment schedule.
Response assessment Primary endpoints. The primary effi-
cacy outcome determination can be the response of the patient
as determined by SCORAD assessment.220,222,223,225–227 A
response may be judged as a CR (defined as ≥95% reduction of
SCORAD), PR (≥50% reduction of SCORAD), minor response
(≥25% reduction of SCORAD); or no response (<25% reduction
in SCORAD). SCORAD assessment should be performed at
baseline, at each 2-week visit during the treatment period for the
first 12 weeks, and thereafter every 4 weeks or at longer intervals
depending on the individual ECP treatment schedule. Together
with SCORAD, the quality of life of patients should be assessed
using tools such as the Dermatological Life Quality Index233–235
or SKINDEX, SF-36 or FACT scores.220
Secondary endpoints. The extent of topical steroid sparing and/
or reductions in serum IgE, eosinophilic cationic protein and
sIL-2R from the start may be considered as secondary end-
points of response to ECP treatment.213,214,220 The assessment of
levels and function of circulating CD4+CD25+ bright Treg-cells29
may be of additional help to predict, identify and/or monitor
AD patients who respond to ECP.
Type 1 diabetes
T1D is a common and serious disease with an increasing inci-
dence worldwide. It is regarded as an autoimmune disease, med-
iated by self-reactive T cells against pancreatic insulin-producing
b-cells. Despite the use of intensive treatment with multiple daily
injections of insulin and self-monitoring of blood glucose, T1D
produces substantial morbidity and mortality.236,237 Residual
insulin secretion facilitates metabolic control and reduces the
risk of ketoacidosis,238 and even modest b-cell function has been
reported to reduce long-term complications.239 Moreover, the
drive to save b-cells and improve their function has become even
more pertinent since some studies have indicated that b-cells
may regenerate.240 If so, there is new hope for the prevention
and treatment of this disease.
It is not known what precipitates or stimulates the autoim-
mune process against b-cells. Viral infections may be important
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(e.g. coxsackie virus, CMV, Epstein–Barr virus, rota virus) as
well as nutritional agents from cow’s milk proteins or gluten.
Another hypothesis suggests that increased demand for insulin
(because of, e.g. increased weight, reduced physical exercise,
increased psychological stress), and a consequent burden on b-
cells, leads to the presentation of autoantigens and possibly heat
shock proteins, which may precipitate an autoimmune reaction
leading to insulitis in genetically predisposed individuals whose
immune system has lost balance. Causes of a less well-balanced
immune system could include increased hygiene and/or abnor-
mal gut flora. Autoreactive T cells (CD4+ and CD8+ cells) are
implicated as active players in b-cell destruction, while autoanti-
bodies, often detected prior to clinical disease, are considered as
markers of an ongoing disease process in the pancreatic islets.
The autoantibodies react against either the islet cells, specific au-
toantigens such as insulin autoantibodies against insulin, glu-
tamic acid decarboxylase, tyrosine phosphatase or zinc transport
antigen.241
Several immune interventions have been tested, with the aim
of preserving residual b-cell function, but to date these have
been associated with insufficient efficacy and/or unacceptable
adverse effects.242–247 There is a need for interventions that do
not suppress, but rather modulate and rebalance, the immune
system, or that create tolerance to the autoantigens involved in
the autoimmune process.
In the non-obese diabetic mouse model of T1D, delivery of
ECP-treated cells significantly delayed the development of T1D.
The combination of ECP-treated cells with b-cell antigens
appeared to improve the efficacy of ECP cell therapy. ECP
induced FoxP3+ Treg-cells, suggesting that it may provide pro-
tection from T1D through the promotion of immune regulation.
ECP-treated spleen-cell therapy also induced suppression of the
immune response to b-cell antigens. Furthermore, in contrast to
ECP-treated cells alone, the combination of ECP-treated cells
with b-cell antigens appeared to improve the protective effect, as
shown by the marked reduction in insulitis in the islets. These
results indicate that the protective effects of ECP against T1D
include suppression of T-cell responses to autoantigens and pro-
duction of Treg-cells. They also suggest that combined therapy
may be required to optimize ECP therapy for T1D. For instance,
combination of ECP with b-cell antigens might provide a more
potent protective effect.248
To date, there is only one reported well-designed study in
which ECP has been used in newly diagnosed patients with
T1D.41 This was a double-blind, controlled study, using placebo
tablets and sham ECP in the control group. A total of 49 children,
aged 10–18 years at diagnosis of T1D were included; 40 patients
completed the study, five double ECP/placebo treatments were
given over a 3-month period and patients were then followed up
for 3 years (19 received active treatment with ECP and 21
received placebo treatment). The ECP-treated children secreted
significantly more C-peptide in the urine during follow-up than
the control group. C-peptide values in serum showed corre-
sponding differences between the two groups. The insulin dose/
kg bodyweight required to reach HbA1c targets was always lower
in the ECP group, although there was no difference in HbA1c
values between the groups during follow-up. ECP was well
tolerated.
In conclusion, clinical and experimental findings suggest that
ECP might influence and delay the disease process in T1D by
enhancing the production of Treg-cells and having an immuno-
suppressive effect. The efficacy of autoantigen treatment may be
increased by ECP, which might be regarded as a sort of vaccina-
tion of transformed autoreactive T cells.
Existing clinical guidelines
None.
Recommendations
Experience is very limited and, at present, ECP should only be
used in the treatment of T1D in well-designed clinical trials,
which is an opinion supported by previously published guide-
lines.74
Pemphigus
Eleven patients with drug-resistant, severe pemphigus (nine with
pemphigus vulgaris and two with pemphigus foliaceus), who
had cutaneous and mucous membrane involvement, underwent
ECP.249–253 OR was 91% (10/11 patients), with 73% (8/11)
having a CR, 18% (2/11) having a PR and 9% (1/11) having
stable disease. A retrospective analysis of eight patients with PV
treated with ECP on two consecutive days at 4-week intervals
reported a CR in all but one patient after 2–6 (mean 4.5) cycles.
Prednisolone doses could be tapered in all patients.254 Three
patients with recalcitrant foliaceus pemphigus who received ECP
achieved one CR and two PRs.251,253,255 ECP was performed
every 2–4 weeks for a minimum of two cycles, allowing the
doses of combined therapies, including corticosteroids and im-
munosuppressants, to be tapered. Decreased levels of circulating
anti-intercellular substance autoantibodies have been reported.
Existing clinical guidelines
The British Association of Dermatologists’ guidelines, published
in 2003, concluded that ECP could be considered in recalcitrant
cases of PV for which more conventional therapy had failed.256
The strength of the recommendation was B (fair evidence to
support the use of the procedure) based on quality of evidence
III (opinions of respected authorities based on clinical experi-
ence, descriptive studies or reports of expert committees).
Recommendations
Patient selection ECP can be considered for those patients with
recalcitrant PV or foliaceus pemphigus, in whom conventional
© 2013 The Authors. Journal of the European Academy of Dermatology and Venereology
published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.JEADV 2014, 28 (Suppl. 1), 1–37
26 Knobler et al.
therapy and second-line interventions (such as immunoabsorp-
tion, rituximab and intravenous immunoglobulins) fail.
Treatment schedule
• Initial treatment during weeks 0–12 should be one cycle of
two treatments every 2–4 weeks, followed by one cycle of
two treatments every 4 weeks during weeks 12–24 until
complete remission.
• After 24 weeks, treatment should be tapered according to
clinical response (e.g. increasing the treatment intervals by
1 week every 3 months).
Response assessment The clinical response should be moni-
tored by two currently accepted clinical scores: the Autoimmune
Bullous Skin Disorder Intensity Score (ABSIS) and the Pemphi-
gus Disease Activity Index (PDAI).257 In addition, the determi-
nation of autoantibody titres should also be performed, at least
in pemphigus vulgaris.
Epidermolysis bullosa acquisita
No series of epidermolysis bullosa acquisita (EBA) patients trea-
ted with ECP has been reported. Eight patients with very severe
EBA, resistant to several systemic immunosuppressive or immu-
nomodulatory agents that caused severe adverse effects, have
been described.254,258–260 The number of ECP sessions ranged
from 3 to 32, given at 3- to 4-week intervals. The OR was 88%
(7/8 patients), with 50% (4/8) of patients achieving a CR. The
time to CR was short: 6–8 weeks of ECP. It is worth noting that
two patients were able stop ECP-combined drugs and did not
relapse after ECP tapering, unlike the patients reported by Sanli
and colleagues.254 After ECP, circulating antibasement membrane
zone autoantibodies were no longer detected in the four patients
with positive tests at the start of ECP. The only major adverse
events were observed in a patient who developed herpes zoster
and pneumococcal sepsis during steroid tapering and idiopathic
cardiomyopathy 14 months after the last cycle. Reported follow-
up lasted 11–24 months for five patients.
Existing clinical guidelines
None.
Recommendations
Patient selection ECP could be a therapeutic option for severe
EBA recalcitrant to conventional systemic therapy [according to
local guidelines (e.g. cyclosporine, mycophenolate mofetil, im-
munoadsorption, rituximab and intravenous immunoglobu-
lins)].
Treatment schedule
• Start treatment 3 months after initiation of conventional
therapy; no wash-out period is required.
• Initial treatment during weeks 0–12 should be one cycle of
two treatments every 2 weeks, followed by one cycle of two
treatments every 4 weeks during weeks 12–24 until CR.
• After 24 weeks, treatment should be tapered according to
clinical response (e.g. increasing the treatment intervals by
1 week every 3 months).
Response assessment The clinical response should be moni-
tored by two currently accepted clinical scores (ABSIS and
PDAI).257
Erosive oral lichen planus
The first series of seven patients with severe, multiresistant, his-
tologically proven chronic erosive oral lichen planus (EOL) were
treated successfully with ECP.261 Time to improvement was
rapid: 1.5 months on average, with all patients having a CR after
a mean of 12 ECP sessions. No recurrence was observed after
ECP discontinuation, with the longest follow-up of 24 months
thereafter.
Other studies have tested the efficacy of ECP for EOL, includ-
ing case reports262–265 and one open study on 12 patients,266 in a
total of 26 patients. In all those reports, ECP regimens differed
widely, from one cycle every week to one cycle every month. OR
was 100%, with 77% CR and 23% PR. Healing of the genital and
cutaneous lesions in nine and five patients, respectively, paral-
leled that of their oral lesions.264, 266 Clinical improvement could
be seen as early as 1.5 months, and almost 1 year of ECP ses-
sions could be required to achieve CR. Although no relapse was
mentioned in the initial article with brief follow-up, ECP had a
palliative effect, as EOL recurred in 12 out of 13 patients during
either ECP therapy or long-term follow-up, at a mean of
8.3 months after ECP withdrawal.264, 266 However, relapses were
sensitive to ECP reintroduction. ECP was extremely well toler-
ated, with lower lymphocyte counts observed in a few
patients.264, 266
Existing clinical guidelines
None.
Recommendations
Patient selection ECP could represent an alternative therapy
for recalcitrant EOL, when previous classical treatments, includ-
ing topical and/or systemic therapies, have failed.
Treatment schedule
• Initial treatment during weeks 0–12 should be one cycle of
two treatments every 2 weeks, followed by one cycle of two
treatments every 4 weeks during weeks 12–24, until CR.
• After 24 weeks, treatment should be tapered according to
clinical response (e.g. increasing the treatment intervals by
1 week every 3 months).
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Response assessment Disappearance of the oral lesions.
Lupus erythematosus
Non-specific anti-inflammatory and immunosuppressive drugs,
such as non-steroidal anti-inflammatory drugs, corticosteroids,
thalidomide, antimalarial and cytotoxic agents, are the standard
treatments to control lupus erythematosus (LE). These drugs,
however, have a hazard of serious side-effects and poor tolerabil-
ity. Recently, advances in molecular biology and immunology
have allowed a greater understanding of the mechanisms
involved in LE pathogenesis,267 and have supported the develop-
ment of biological agents targeting a variety of pathologic path-
ways. These new drugs have given promising results in
experimental clinical trials, but are unapproved as yet.268,269
Although ignored by international guidelines 268 and expert
reviews,269 preliminary results indicate that ECP could represent
an innovative effective and safe therapeutic option for the treat-
ment of LE.
Eighteen female patients with LE have been treated with ECP
to date.270–274 All had mild-to-moderate disease activity that was
not adequately controlled with standard treatment options and/
or they had a flare of disease activity upon attempted reduction
and/or elimination of these drugs. Eight patients were affected
by systemic LE (SLE), six by subacute cutaneous LE (one was
affected by lupus tumidus too) and three by disseminated dis-
coid LE. One patient had lupus tumidus, lupus panniculitis and
chilblain lupus. Ten patients reported photosensitivity. In all but
one report,272 ECP cycles consisted of two ECP sessions on con-
secutive days at monthly270,271,275 or bi-monthly273,274 intervals
until remission. Afterwards, the treatment was interrupted or
performed with longer intervals to maintain remission, if any.
A marked remission or CR leading to withdrawal (or a sub-
stantial decrease of dosage) of corticosteroid and cytotoxic drugs
was seen in 16 patients. In the case series reported by Knobler
and colleagues,270 some patients had other LE lesions (i.e. arthri-
tis, arthralgias and myalgias) that improved as well. Of note was
the fact that ECP sessions did not induce exacerbation of other
SLE symptoms, regardless of whether or not the patients were
photosensitive.270–274 Remission was prolonged (up to 4 years)
in many patients, even without maintenance ECP cycles.271,273
In one patient, an early relapse was seen, but lesions were ame-
nable to another treatment cycle.271 Marked changes in specific
routine laboratory parameters and autoantibody levels were
never registered.270–274
In the case series reported by Knobler and colleagues,270
hypovolaemic hypotension was documented in one patient
during the ECP procedure and three patients were found to
develop nausea after ingestion of the 8-MOP capsules. One
patient died 6 months after initiation of the ECP programme,
with death occurring 10 days post-ECP, so a relationship to ECP
treatment could not be ruled out, although autopsy did not
demonstrate pulmonary embolism or occluded arteries.270 ECP
cycles were without unwanted side-effects and well tolerated in
the remaining patients.271–274
In summary, the use of ECP in LE is supported by poor clini-
cal evidence (i.e. results from individual case reports or small
case series with different treatment protocols and short follow-
up). Therefore, it must be considered only at an exploratory
stage. However, the preliminary clinical results are positive and
future randomized, controlled clinical trials should be encour-
aged to assess therapeutic efficacy and cost-effectiveness. In
addition, length of therapy, design of specific protocols, con-
comitant use of immunosuppressive therapy, patient character-
istics and long-term side-effects should be assessed.
Other indications
ECP has also been used in prospective studies in a number of
other disease areas, including psoriasis,276 rheumatoid arthri-
tis,277–279 multiple sclerosis,280–283 nephrogenic fibrosing derm-
opathy,284–286 and scleromyxoedema,287,288 with inconclusive
evidence.
Summary/Conclusions
It is now 25 years since the results of the first prospective, multi-
centre, international clinical study on the use of ECP for treat-
ment of CTCL were published by Edelson and colleagues,
leading to FDA approval of ECP as the first cellular immuno-
therapy for cancer. Since then, ECP has been investigated for
prevention and treatment of a variety of T-cell mediated diseases
as described in this publication. In many of these diseases there
are now sufficient data from retrospective and, increasingly, pro-
spective single and multi-centre clinical trials with ECP to enable
recommendations to be made on which patients should be trea-
ted, the ECP treatment regimen to be used and how treatment
should be monitored. Our recommendations are summarized in
Table 8.
ECP is a well-tolerated therapy with an excellent safety profile.
No significant side-effects have been reported in any of the
conditions reviewed here, except for the short-term effects of
oral 8-MOP when this was used in early studies. Unlike other
immunosuppressive therapies, ECP has not been associated with
an increased incidence of infections. New technical develop-
ments allow it to be used in children and have also substantially
shortened treatment times. Furthermore, whereas ECP has, in
the past, been used empirically within the clinic, recent preclini-
cal and clinical research is now throwing light on the complexi-
ties of its mechanism of action. In addition, promising data are
also emerging on the identification of biomarkers predicting
response to ECP, which are urgently needed in an environment
where there is a rising demand for efficient use of limited
resources.
The advances during recent years have established ECP as a
recognized and accepted immunomodulatory therapy with
the potential to induce tolerance. It seems likely that greater
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understanding of how ECP works and extension of its clinical
use will enable the value of ECP to be extended into the future.
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